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Investigation of the Critical Factors in the Early Stage of the Innovation   
Process in Biotechnology: A System Dynamics Approach      
Elham Tayaran 
Introducing new products and innovations plays an important role in changing the 
competitive paradigm of biotechnology. Considering the valuable, rare and unique 
capabilities that innovations provide, the firms must understand the crucial factors 
affecting their success in innovation and how to manipulate these factors to enhance their 
performance. The two important stages of innovation are the front end of innovation and 
new product development. The first stage has an important effect on the outcome of the 
innovation process in biotechnology. Although the main factors that impact these firms‘ 
innovative activity in the early stage have been determined in literature, the details about 
the relationship between them still remain unclear. In order to facilitate a better 
understanding of the dynamic behaviour of these interactions and feedback mechanism, a 
System Dynamics simulation model, demonstrating the early stage of innovation in 
biotechnology, is developed. Using this methodology, we create a dynamic learning 
environment to explore the effectiveness of using either internal or external sources of 
knowledge as innovation strategies. Different scenarios have been tested to identify the 
impacts of the firm‘s innovation policy on its innovative performance. It was found that 
focusing on the exploitation of external sources of knowledge is a suitable strategy for an 
increase in the target knowledge, however it should be deployed considering internal 
factors such as the R&D expenditure and the firm‘s initial policy regarding either of the 
sources of knowledge. The main contributions of this thesis involve the identification of 
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the influential factors of the early stage of the biotechnology innovation process, the 
examination of their interactions and the final recommendations in terms of the firms‘ 
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1.1. Introduction  
The importance of biotechnology activities in today‘s economy is emphasized by 
many authors (Afuah, 2002; De Carolis, 2003; Nicholls-Nixon and Woo, 2003; Zott, 
2003; Galbreath, 2005, Baker, 2003). In Canada, biotechnology is considered as one of 
the most dynamic and strategic high-technology sectors, providing a significant 
contribution to science advancement and innovation, thousands of jobs, as well as large 
exports. Canada ranks second in terms of the number of biotechnology firms in the world, 
after the United States (Van Moorsel et al., 2007). The important role that biotechnology 
activities play in the Canadian economy is often discussed in literature (e.g. Traore, 
2004).  Canada‘s educated population, proximity to the United States, and availability of 
research and development facilities provide suitable conditions for successful 
biotechnology businesses to grow in Canada (Van Moorsel et al., 2007).  
Obviously, Canadian firms‘ competitiveness in biotechnology highly depends on 
their ability to introduce new products and innovations. Innovations provide firms with 
valuable, rare and unique sources of capabilities to establish and sustain a competitive 
advantage (Barney, 1991). Innovative firms have the flexibility to change the existing 
technological patterns and shape new trajectories; such firms can easily reinvent 
themselves or develop new businesses (Burgelman, 1983). Innovations enable the firms 
to better satisfy the existing customers‘ needs and desires, to attract completely new 
customers and to enter new markets. The innovation process should thus receive the 
utmost attention in the corporate planning of every company.  
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The innovation process can be divided into two main stages: front end of innovation 
and new product development (Herstatt and Verworn, 2001). Front end of innovation 
precedes the formal and structured process of new product development. Its role is to 
produce ideas for new product concepts and to select the ideas that fit with the firm‘s 
business strategy. The importance of early stage activities in the success of the innovation 
process has been emphasized by many studies (Kim and Wilemon, 2002; Khurana and 
Rosenthal, 1998; Brem and Voigt, 2009). According to Cooper and Kleinschmidt (1994), 
―the greatest differences between winners and losers were found in the quality of pre-
development activities.‖ Even though the front end of innovation clearly creates the 
groundwork for the whole innovation process and is generally regarded as one of the 
greatest opportunities for improvement (Koen et al., 2001), the existing innovation 
models found in literature most often consist only of the new product development phase, 
while the front end of innovation stage is omitted or trivialized. 
Decision making during the early stages of innovation has a great effect on the 
outcomes of technology-oriented companies. In biotechnology, which is highly research-
intensive, the importance of research and development (R&D) activities and other 
practices that precede the formal process of the development of a new product is even 
more pronounced. However, research focusing on the biotechnology innovation process 
is quite rare. The innovation process in biotechnology is usually presented as a set of 
sequential activities (Hall and Baghchi-Sen, 2002). This linear model demonstrates 
neither the interactions of various determinants of innovation nor their influence on the 
firm‘s performance (Hall and Baghchi-Sen, 2002; Khilji et al., 2006). The real innovation 
process in biotechnology is more complex and iterative, and thus it needs to be 
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investigated through more appropriate methods to reveal all of its complexities and 
interdependencies.   
The presented thesis intends to shed some light on this important but still 
undiscovered and blurred part of the innovation system. The thesis‘ main objective is to 
improve the understanding of the dynamics of the technological innovation through the 
design of the dynamic model representing the early stage of the biotechnology innovation 
process and through the subsequent simulation of this model. This will allow us to 
evaluate the factors that have an impact on the innovation process and to investigate those 
organizational policies that can enhance the outcome of this process.  
This thesis is structured as follows: Chapter 2 reviews the related literature in 
innovation, with a special focus on the front end of innovation and reports the research 
questions; Chapter 3 presents a brief review of the main concepts of system dynamics 
methodology that are used in this research; Chapter 4 discusses the variables of the 
model, where their relationship is introduced and defined; Chapter 5 reports the results of 
the simulation and discusses the main findings; Lastly, Chapter 6 draws the main 






2. Literature review and research objectives 
2.1. Innovation 
2.1.1. Definition  
Being innovative, which means bringing new products into the market, is the key 
factor for organizations to maintain their competitiveness and survival in the market. 
New technologies, changing customer needs and the shorter life cycle of existing 
products force firms to introduce innovations in order to ensure their long-term 
sustainability. Otherwise, their place would be taken by other companies in the 
marketplace (Utterback, 1994).  
Innovation is defined as the creation, development, and implementation of ideas that 
result in new or improved products. These ideas have practical or commercial benefits 
(Zaltman et al., 1973; Van de Ven, 1986; Damanpour, 1991), but not all of the ideas will 
end up as new products, and this is what constitutes the difference between invention and 
innovation. Based on Porter‘s study (1990), innovation consists of commercialization, 
whereas invention does not.  
Another definition, proposed by Rainey (2005), states that ―Innovation involves 
changes and improvements to technologies, products, processes, and services that result 
in positive contributions for customers and other constituents of business organizations‖.  
 
2.1.2. History 
The early innovation processes consisted of generating the ideas, testing the ideas, 
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developing the ideas into products, and eventually launching the products to a market. It 
was initially believed that it was only a few people (such as owners or stakeholders) who 
managed the process and who decided on whether to eliminate or keep a new project 
(Axelrod, 2008). As it can be implied, the important decisions and much of the 
innovation process depended highly on the knowledge of stakeholders.  
Companies started accepting the funnel concept in their R&D process later, possibly 
in the 1930 or 1940s. The funnel concept made it possible for a firm to evaluate and 
develop many ideas while managing their costs and risks. The funnel is named based on 
the notion that at the beginning, a firm generates many ideas but only a few preferable 
ideas are eventually funnelled down through the R&D process. Since the progress 
through the R&D process accumulates greater and greater expenses, using the funnel 
concept helped with evaluating and ignoring less preferable ideas as early as possible in 
the new product development process, and thereby not only reducing the risk of 
developing undesirable new products, but also managing the cost. The above process was 
divided into two main parts around the 1930s or 1940s:  
1) R&D process  
2) New product development and commercialization processes. 
The study of innovation has attracted much interest since the 1980s, when companies 
realized that their future was strongly affected by their ability to innovate. Books with 
titles like ―Innovate or Die‖ (Matson, 1996) and quotes like ―Company has two functions: 
innovation and marketing, everything else are just expenses‖ (Drucker, 1985) were just a 




2.1.3. Concept  
Innovation is a process of converting opportunities into something for practical use 
(Tidd et al., 1997). In addition to creating a competitive advantage for companies, 
organizations also found innovation to be the major factor of economic growth and 
wealth of a nation (Galanakis, 2006). Other researchers (Lundvall, 1992; Porter, 1990; 
Freeman and Soete, 1997; Stoneman, 1995) considered innovation as the socio-economic 
driver for growth. As it was argued by Sundbo (1998) and also supported by Galanakis 
(2006), governments could even solve the economic and social problems of their 
countries, such as productivity and unemployment rates, by promoting innovation. 
However, they are not always successful (Galanakis, 2006).  
Furthermore, two types of innovation are identified in literature based on the levels 
of innovativeness: incremental innovation and radical innovation. Incremental 
innovations are defined as minor improvements to existing products by using existing 
technology and are targeted for the existing market (Reid and de Brentani, 2004; Munson 
and Pelz, 1979). Radical innovations are characterized by fundamental changes in the 
technology used compared to the earlier product (Balachandra, 1997). Utterback (1994) 
called innovation ―a life-or-death ingredient‖ for a firm. He suggests that incremental 
innovations are created in order to meet today‘s market demands, but in order to assure 
long-term survival, the firms need to generate radical innovations as well.  
Innovation is a creative new solution in response to the frequently expressed and 
latent needs of customers and stakeholders. The importance of innovation has been 
widely recognized because of its major role for sustaining the prosperity of most 
organizations and companies. Considering the importance of having new products in the 
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market and the cash flow as a result, innovation is the solution to maintain a firm position 
to compete in a demanding world (Rainey, 2005). Innovativeness, in addition to 
establishing a basis for the firms` survival, provides them with the possibility to choose 
different options to satisfy their customers (Banbury and Mitchell, 1995; Koc et al., 
2007). The effective deployment of innovation has been also identified as highly critical 
in order to enhance organizational performance.  
 
2.1.4. Innovation theories  
Given the importance of innovation, four different factors are considered as the 
drivers of product innovation (Cooper, 1999): technological advances, intensified 
customer needs, shorter product life cycles, and increased world competition. 
Furthermore, in order to understand the nature of innovation, several theories about the 
generation of innovation have been identified (Rothwell, 1994). These are classified into 
five groups as follows: 
 
1. The Technology Push Theory  
This theory is based on a simple process in which a new product is pushed into the 
market by scientific and technological advances. This was a prevailing theory in 
1950s. 
 
2. The Market Pull Theory 
This theory involved also a simple process in which the need for a new product is 
created by the market at the time. The theory was dominant in 1960s. 
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3. The Coupling Innovation Process Theory  
This theory, which is a combination push-pull theory, represents innovation as a 
sequential process but not necessarily a continuous one. It consisted of sets of 
interdependent stages and feedbacks to the previous stage. The connections 
between different parts of an organization, in addition to the relations with outside 
of the organization, create a complex net that link together the firm, the 
technological and scientific community and the marketplace (Rothwell and 
Zegueld, 1985). This theory was powerful during the 1970s and early 1980s. 
 
4. The Functional Integration Innovation Process Theory  
This theory drew inspiration from the Japanese in the automobile and electronics 
industries. In this theory, industries take advantage of the different stages of the 
New Product Design and Development (NPDD) process in a parallel mode, instead 
of in a sequential mode. The parallel approach provides a functional integration 
around a project that makes it possible to combine the expertise of the different 
specialists. This arrangement results in reducing the completion time and the 
rework that may be required at later stages of the process (Imai et al., 1985).  
 
5. The Systems Integration and Networking Innovation Process Theory 
This theory was founded based on the previous one, but it emphasizes the need for 
continuous change. Creating a network of suppliers, customers and other firms is 
suggested to resolve the problem of the higher complexity of new products. 
Furthermore, using new tools and technologies such as simulation and rapid 
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prototyping in the innovation process facilitates the process during the design and 
development stages. In fact, efficiency and speed in this process are the key 
benefits, derived mainly from continuous interactions across the innovation 
network.  
 
6. The System of Innovation Theory 
A new generation theory was developed in the 1980s and the 1990s. This theory 
aims at identifying the social and economic effects of the process that generate 
innovation across a nation. The sixth generation theory tries to relate the policy of 
innovation players and the ability of firms to innovate, which could affect the 
wealth of a nation (Sundbo, 1998; Edquist, 1997). As mentioned by Chang and 
Chen (2004) ―the system of innovation approach is useful because it makes it 
possible to describe, understand, explain and influence the process of innovation‖. 
The factors that have an impact on innovation can be identified by studying the 
system of innovation (SI). One of the SI approaches is the national system of 
innovation.  Chang and Chen (2004) quote Freeman‘s (1987) definition for NSI as 
―the network of institutions in the public and private sectors whose activities and 
interactions imitate, import, modify and diffuse new technologies‖. 
 
2.1.5. Main components 
Herstatt and Verwon (2001) proposed that the innovation process (see Figure 2.1) 
consisted of two main stages: Front End of Innovation (FEI) and New Product 





Figure ‎2.1 Two main components of the innovation processes (Herstatt and Verwon, 2001) 
FEI, which was initially popularized by Smith and Reinertsen (1991), is the first 
stage of the innovation process. This stage is also addressed by the term Fuzzy Front End 
(FFE). According to Herstatt and Verwon (2001), idea generation and concept 
development are the main activities of the FEI. Additionally, this term is defined by Reid 
and de Brentani (2004) as the initial stage of idea development and the time and activities 
spent on the idea to make it ready for the development stage. FEI is then followed by the 
NPD stage. New product development is a stage in which a new product is developed and 
launched to the market. Substantial commitments in time and monetary terms are made 
during this stage. This stage compared to the earlier stage is more structured, goal 
oriented and linear. The NPD process has been studied in the scientific community from 
different angles and it has been subjected to modeling on multiple instances (Milling, 
2002). The modeling-based research concentrated mostly on understanding the flows in 
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the innovation process from an operational level with a focus on project implementation 
and project management (Ford and Sterman, 1998). Thus far, the majority of researchers 
have addressed only the process of NPD and the dynamic relationships among them 
(Milling, 2002), and compared to NPD, FEI has been investigated to a lesser extend in 
the literature. 
 
2.2. Fuzzy Front End 
2.2.1. Introduction  
As it was mentioned, the front end of innovation (FEI) is the first stage of the 
innovation process. This stage has been labelled by different terms in the literature, e.g. 
as the ―early stages of the product development‖ (Nobelius and Trygg, 2002; Khurana 
and Rosenthal, 1998), ―early phases of innovation, early innovation phases‖ 
(Lichtenthaler et al., 2004), ―pre-development‖ (Cooper and Kleinschmidt, 1994; Hüsig 
and Kohn, 2003), ―pre-project activities‖ (Verganti, 1997), ―Fuzzy Front End (FFE)‖ or 
―pre-phase 0‖ (Khurana and Rosenthal, 1997, 1998; Koen et al., 2001). In this research, 
the terms ―fuzzy front end (FFE)‖ and ―early phase of innovation‖ are used 
interchangeably in order to refer to the first stage of the innovation process. 
Frequently in the literature, the term ―Fuzzy Front End‖ is used for addressing the 
first stage of innovation (Khurana and Rosenthal, 1997, 1998; Verwon et al., 2008; 
Zhang and Doll, 2001; Kim and Wilemon, 2002; Reid and de Brentani, 2004). The 
ambiguous term ―Fuzzy‖ was first used by Smith and Reinertsen (1991). The term has 
been used differently by scholars in the field. For example, the word ―fuzzy‖ emphasizes 
the uncertain and unpredictable nature of the front end of innovation process (Koen et al., 
12 
 
2001). Likewise, fuzziness is considered by Kim and Wilemon (2002) as the ambiguity 
about technology, market, required resources and strategy-fit with the company. Zhang 
and Doll (2001) separated front end activities from front end fuzziness and argue that 
embedded fuzziness in this stage is due to environmental uncertainty. Finally, Hüsig et al. 
(2005) believed that this fuzziness comes from the perception that the front end activities 
are unstructured and not sequential.  
The early phase of innovation has many definitions in the literature. The definition 
usually states the type of activities which take place in the early phase of innovation. 
Basically, ―those activities that take place prior to the formal, well-structured New 
Product and Process Development‖ (Koen et al., 2001) are involved in the early phase. In 
other words, the early phase of innovation is the stage in which ―organization formulates 
a product concept and determines whether or not it should invest resources to develop the 
idea‖ (Kim and Wilemon, 2002).  
 
2.2.2. The early phase of innovation activities 
The activity-based definitions of the early phase of innovation can help with 
understanding the activities which take place in this stage, however further clarification is 
required. Khurana and Rosenthal (1998) defined FFE as the stage which includes 
―product strategy formulation and communication, opportunity identification and 
assessment, idea generation, product definition, project planning and executive review.‖ 
According to Cooper (1988), the main activities are ―generation of ideas, initial 
screening, preliminary evaluation, and concept evaluation‖. Similarly, Hüsig et al. (2005) 
proposed three general phases for the early phase of innovation: opportunity 
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identification, idea generation and finally concept development. 
There is no common agreement as to the deliverables and results at the end of the 
early phase of innovation. Nevertheless, a well-defined product concept, product 
definition, development requirements and business plan with respect to the firm strategy 
are the common results of this stage (Kim and Wilemon, 2002). In addition, it was noted 
that the early phase of innovation or FFE should create a formal project plan to be 
executed in the development stage (Nobelious and Trygg, 2002; Koen et al., 2001; 
Khurana and Rosenthal, 1997). Moreover, deliverables at the end of FFE vary widely 
from industry to industry. 
 
2.2.3. Importance of the early phase of innovation 
Different studies claim that the performance of early stage activities significantly 
affects the success of the new product development process (Kim and Wilemon, 2002; 
Khurana and Rosenthal, 1998; Brem and Voigt, 2009). According to Cooper and 
Kleinschmidt (1994) ―the greatest differences between winners and losers were found in 
the quality of pre-development activities.‖ It is also argued that the final outcome 
resulting from the improvement in the early phase activities is much more valuable than 
the one which is brought about by the improvement in the design engineering process 
(Zhang and Doll, 2001).   
The early phase of innovation is also called ―the root of success‖ for discontinuous 
product innovation (Reid and de Brentani, 2004). The study of Cooper and Kleinschmidt 
(1988) revealed that generally the pre-development activities received fewer amounts of 
resources (only at 6% of dollars and 16% of man-days of the total) in comparison to the 
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practical stages of development and commercialization. Interestingly, by observing the 
success process, Cooper and Kleinschmidt (1988) noted that companies which succeeded 
in product development had spent twice as much money and time on the early phase 
compared with the money expended on unsuccessful projects.  
The empirical findings from the study conducted by Verwon (2009) provide 
additional support for the importance of fuzzy front end activities for the project 
execution and project success. Nevertheless, even though many researchers emphasized 
the importance of the early phase of innovation, only a few references gave details on why 
it is in fact so essential. The following reasons were pointed out by Glassman (2009) to 
elucidate the vital role of FFE in the innovation process: 
 
1. The costs involved in the innovation processes are the first obvious reason that 
clearly illustrates the value of the early phase of innovation. 
  
2. The early phase of innovation is directly responsible for introducing high quality 
ideas into the innovation value chain or new product development (NPD) 
processes.  
 
3. The early phase of innovation activities could reduce the uncertainty, which in turn 
can result in better achievements in terms of concepts, project plans, and selections 
of tasks for the project during the new product development process.  
 
4. Finally, having a deep understanding of the early phase of innovation would aid 
companies in generating and selecting those ideas which could fit with the 
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company‘s capabilities and strategies.  
Figure 2.2 shows the characteristics of fuzzy front end (Herstatt and Verwon, 2001). 
According to Herstatt and Verwon (2001), different methods and tools can be applied for 
managing innovation and analyzing the front end of innovation based on the amount of 
available information about the market and technology. 
 
 
Figure ‎2.2 The characteristics of FFE during the innovation process (Herstatt and Verwon, 2001) 
 
2.2.4. Structured or unstructured fuzzy front end  
Using a structured or an unstructured fuzzy front end has been matter of debate 
between researchers. While some authors (Tang, 1998; Benner and Tushman, 2002; Reid 
and de Brentani, 2004; Nobelius and Trygg, 2002; Poskela and Martinsuo, 2009; 
Markham et al., 2010) believed in unstructured early phase of innovation, some scholars 
argued that formal and structured process in the early phase leads to more successful 
products (Khurana and Rosenthal, 1998; Montoya-Weiss and O‘Driscoll, 2000).  
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Furthermore, Hüsig et al. (2005) empirically showed that better FFE results could be 
obtained from a structured FFE. Process formalization is defined by Poskela and 
Martinsuo (2009) as ―specifying procedures to be followed and monitoring that work 
activities are proceeding in accordance with the defined procedures.‖  Poskela and 
Martinsuo (2009), who are opposed to a formal process for early phase of innovation, 
pointed out that the identified benefits of having a formal process are typically provided 
without taking into careful consideration the different types of innovation or front end 
projects. 
Most of the formal FFE processes have been criticized because they tend to adopt 
one single FFE process for the early phase of innovation with no regard to the contextual 
factor. For example, Nobelius and Trygg (2002) illustrated that there is no one best model 
for the early phase of innovation. They argued that, although the main activities of the 
early phase of innovation always include a mission statement, concept 
generation/screening/definition, business analysis and finally project planning, their 
sequence, duration of each activity, level of assigned resources and perceived importance 
would differ based on the type of project and type of industry. On the other hand, it was 
concluded (Hüsig et al., 2005) that structured early phase processes could result in better 
technical and market info, creating more satisfying results for the NPD managers, and 
also better patent portfolios.  
 
2.2.5. The lack of research on the early phase of innovation 
To date, despite the identified importance of the early phase of innovation, this stage 
is the greatest weakness in the innovation process studies. Many researchers noted that in 
17 
 
comparison to the research on the new product development process, little research has 
been done on the early phase of innovation itself (Kim and Wilemon, 2002; Khurana and 
Rosenthal, 1998, 1997; Nobelius and Trygg, 2002; Zhang and Doll, 2001; Reid and de 
Brentani, 2004; Brem and Voigt, 2009; Koen et al., 2001; Poskela et al., 2005). For 
example, Koen et al. (2001) mentioned that in the early phase of innovation, there is even 
no common language or definition of the important elements of this stage. Similarly, 
Murphy and Kumar (1997) proposed two reasons for the lack of research in this area: 
 
- The early phase of innovation is a dynamic and unstructured stage; hence these 
characteristics make the early phase difficult to study. For example, the creativity 
degree of the organization highly affects the idea generation process and as a 
result makes conceptualizing this process challenging. 
 
- Unlike the NPD stage, the early phase of innovation is characterized by a high 
level of informality, therefore it can be seen that firms mostly rely on accepted 
rules for developing product concept. This issue makes it difficult to provide the 
best practice of the early phase of innovation. 
 
2.3. Process models of the early phase of innovation 
As stated above, there have only been very few studies on the early phase of 
innovation, compared to the new product development phase that has attracted much 
greater research attention. As argued by Cooper and Kleinschmidt (1990), the early phase 
of innovation was initially limited to one factor e.g. the ‗quality of predevelopment 
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activities‘. However, since the 90‘, more detailed studies have been carried out to shed 
some light on the early phase of innovation (Kim and Wilemon, 2002; Herstatt and 
Verworn, 2001; Nobelius and Trygg, 2002; Khurana and Rosenthal, 1998, 1997; Murphy 
and Kumar 1997; Moenaert et al., 1995; Zhang and Doll, 2001; Reid and de Brentani, 
2004; Poskela et al., 2005).  
Theoretical consideration and qualitative studies are the two groups comprising the 
majority of the early phase of innovation literature (Verworn, 2009). The following sections 
will describe in detail the most important models in both groups. 
2.3.1. Qualitative Models 
2.3.1.1.   Cooper’s stage-gate process 
Stage gate process (Cooper, 1990) can be considered one of the most commonly 
applied models for managing NPD and also FFE processes. The model is based on a 
simple concept of checking the quality of each stage by putting a control unit after it, 
which is illustrated in Figure 2.3. 
 
 
Figure ‎2.3 The full stage gate model (Cooper, 1990) 
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A stage consists of a set of activities which is followed by a gate to control the 
stage‘s deliverables. The innovation process is divided into predetermined set of stages, 
where the number of stages is varied between four and seven according to the type of 




Figure ‎2.4.The stage gate process (Cooper, 1988) 
The process starts with the idea generation and then the ideas move through the 
process after the best ones are selected. At the first gate, the ideas are screened against a 
set of predefined criteria, then in the next stage, a limited amount of information 
regarding market and technical aspects will be acquired. Accordingly, in each stage more 
detailed information is gathered and the ideas are investigated in depth. The aim is to 
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provide a well prepared business plan that includes the product concept, product 
justification and an action plan for the NPD process.  
Cooper (2008) in his recent paper introduced a next-generation version of the stage 
gate process to improve the model performance. Moreover, he explains some possible 
misconceptions and challenges that are encountered when the stage gate process is being 
used. One often debated issue of the stage gate process is the linearity of the visual model 
(Nobelius and Trygg, 2001; Reid and de Brentani, 2004; Poskela and Martinsuo, 2009). 
In this study Cooper however argued that, although the model visualization is laid out in 
a sequential fashion, each stage includes a large amount of looping and iterations. 
The stage-gate model is considered one of the most linear and formal models to 
manage the early phase of innovation, and as such it has been criticized by the authors who 
disagree with the formality in managing the FFE process. (e.g. Nobelius and Trygg, 
2001; Reid and de Brentani, 2004; Markham et al., 2010; Poskela and Martinsuo, 2009; 
Tang, 1998). For instance, Tang (1998) in his study argued that the stage-gate model 
cannot sufficiently describe some essential characteristics of the innovation process such 
as learning and developing competency. Another criticism comes from Schroeder et al. 
(1989) who claim that Cooper's model is not able to appropriately cope with 
organizational factors. 
Moreover, even with the wide application of this method in NPD, the stage-gate 
model does not include the early FFE activities, like opportunity identification or 
information exploration (Glassman, 2009). Additionally, more focus is applied on 
funnelling the number of poor ideas rather than on looking for new opportunities 
(Poskela et al., 2005). 
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2.3.1.2. Khurana and Rosenthal FFE model 
Khurana and Rosenthal (1997; 1998) proposed a holistic process view of front end 
activities, including foundation elements and project-specific elements. Foundation 
elements, or non-project-specific elements, include product strategy formulation and 
implementation, product portfolio development and product line strategy in order to 
support the decision making of new product development.  
Project-specific elements are activities that help organizations develop a product 
concept, market requirements and finally an action plan. They synthesized these elements 
into the process view as it is illustrated in Figure 2.5. Khurana and Rosenthal (1997) 
emphasize the importance of a structured strategy for dealing with development of a new 
product. They also carefully examined the front end practices in 18 business units from 
twelve U.S and Japanese companies. The authors discovered that those organizations that 
support the holistic approach the early phase of innovation have a higher chance of 
attaining success. The holistic view will be achieved by covering all four key front end 




Figure ‎2.5. A model of FFE process (Khurana and Rosenthal, 1997) 
As seen in Figure 2.5, Pre-Phase Zero activities, which generally involve opportunity 
identification, idea generation and market analysis, are very important for the following 
phase – Phase Zero. In Phase Zero, the customer needs and wants, technologies 
capabilities, product requirements and required resources will be defined. 
The holistic view for managing the early phase of innovation can be achieved by two 
different approaches: formal process or cultural-driven approach. Analyzing multiple 
case studies reveals that the formal process approach is mostly applied by European and 
American firms, whereas the Japanese firms tend to control the front end through strong 
organizational culture and business point of view based on cross-functional interactions. 
Both of these two approaches are considered viable models for implementing a holistic 
front end. 
Although Khurana and Rosenthal (1998) attempted to achieve a better understanding 
of the early phase of innovation, they have primarily focused on incremental innovation. 
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They argued that, although a more formal approach worked well in incremental 
innovations, the processes aiming at radical innovations and products tend to be more 
loosely defined, less structured and less explicit. Other authors (e.g. Nobelius and Trygg, 
2002; Raid and de Brentani, 2004) confirm that formal processes, including the Khurana 
and Rosenthal's holistic process, cannot fulfill the need of the early phase for a radical 
innovation. 
 
2.3.1.3. Koen’s new concept development model 
Another popular process model, which is one of the non-linear and iterative process 
models, is the new concept development model (NCD) developed by Koen et al. (2001). 
They attempted to bring the common language to define the front end of innovation 
processes by the NCD model. They believe that the circular shape of the model indicates 
the flow, the circulation and the iteration of ideas within the FFE process. This is in fact 
considered a major benefit of this model. The model, as shown in Figure 2.6, is made up 
of three key components: inner area, engine and influencing factors.  
 
1. The inner area consists of five elements: opportunity identification, opportunity 
analysis, idea genesis, idea selection and concept development. The arrows 
between the elements show the flow of an idea within the model. The elements 
can interact with each other in a more random and non-sequential manner 
irrespective of their position in the model. Koen et al. (2001) in their model 
demonstrate the inner part of the model as elements rather than processes in 
order to avoid any implied controls that could be used to manage front end 
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activities. The process can start with any of the idea genesis or opportunity 
identification, but it finally results in a concept development. The explicit 
distinction between the opportunity and the idea was not found in either 
Cooper‘s model (1988) or Brem and Voigt‘s model (2009), and thus makes the 
Koen‘s model superior. 
2. The leadership and culture of organization controls the ―engine‖ that feeds 
different elements. Due to the importance of these factors in the new product 
development, the engine is located in the center.  
3. Finally, the influencing factors include business strategy, governmental policy 
and environmental regulations. Since the whole process of FFE is affected by 
these factors, they have been shown in Figure 2.6 as the black wheel 





Figure ‎2.6. The new concept development model (NCD) by Koen et al. (2001) 
 
2.3.2. Theoretical consideration 
2.3.2.1. A Theoretical model of discontinuous innovation  
While the majority of studies so far have only focused on the best practice model for 
the late fuzzy front end, few studies have taken into consideration the early fuzzy front 
end in their model (Reid and de Brentani, 2004). Late fuzzy front end activities are the 
activities and decisions that are involved in idea generation and concept development 
(Cooper, 1990; Urban and Hauser, 1993). Early fuzzy front end activities, which involve 
the identification and the structuring of opportunities and the collection of information, 
have been addressed to a lesser extent (Reid and de Brentani, 2004).  
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Considering the fact that the FFE process highly depends on the type of innovation 
(Khurana & Rosenthal, 1998), understanding the complex nature of the early fuzzy front 
end is very important for developing radical innovations. In this regard, a theoretical 
model of the fuzzy front end information flow and decision-making process has been 
developed for discontinuous (radical) innovations (Reid and de Brentani, 2004). As 
indicated by authors, the theoretical model is built on combining three key perspectives, 
which themselves are also drawn from NPD and TIM (Technology and Innovation 
Management) literature. These perspectives are environmental, individual and 
organizational, and represent the factors that could have effects on decision making in the 
fuzzy front end process. In this study, the fuzzy front end of NPD is described as a string 
of decisions taking place over three proposed interfaces: boundary, gatekeeping and 
project. Figure 2.7 shows the proposed model of FFE. Further, the authors demonstrate 
the nature of fuzzy front end for the discontinuous innovation in the form of a series of 
propositions as follows: 
- In the incremental innovation, the problems or opportunities will be identified by 
an organization and then will they be directed by individuals.  
- In the discontinuous innovation, which is different in the nature from incremental 
innovation, the problems or opportunities will be identified by individuals and the 
subsequent search for further information is also performed by individuals. 
- In case of discontinuous innovation, information for a new idea is obtained from 
the environment by boundary spanning individuals through an interface called the 
boundary interface, stimulated by communication as well as by the perception and 
by the reconstruction ability of individuals. 
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- In the discontinuous innovation, information moves from boundary spanning 
individuals to gatekeeping individuals (often the same person) in the organization. 
This movement is made through an interface called the gatekeeping interface, 
motivated by information sharing. 
- In case of a discontinuous innovation, information flows from the organization to 
the project level through the project interface. Here, the information depends on 
the evaluation of the ideas in the formal first screen and on the degree of the 
match between the ideas and a strategic arena of the firm. However, even a new 
strategic area can be developed during this process. 
 
 




2.3.2.2. FFE and the role theory 
Consistent with Reid and de Brentani (2004), Markham et al. (2010) carried out a 
study in order to understand the set of roles moving a project through the early phase of 
innovation. In their research, the term ―Valley of Death‖ is used to show the activities that 
occurred between the two well-defined activities - research and formal NPD. According 
to the authors, the selection of this term is due to the lack of resources and expertise in 
this stage of development. As argued by Reid and de Brentani (2004), previous 
researches on early phase of innovation focused primarily on the preparatory tasks 
performed before a concept is accepted to a formal NPD. Markham et al. (2010) 
recognized the gap between the activities and the roles of the organization participating in 
this stage of product development and attempted to identify the informal roles, activities 
and processes in the Valley of Death. In their study, they shed some light on the nature of 
work of pre-development stage and propose that there are three major activities in the 
early stage, which are (a) awareness, (b) demonstration, (c) acceptance and transfer. 
These activities are carried out by three key informal, overlapping roles: champion, 
sponsor and gatekeeper. The model is illustrated in Figure 2.8. 
The authors proposed that as the project progresses, the different roles emerge to 
perform relevant activities. At the beginning a champion, whose responsibility is to 
identify the ideas and select them, has the greatest importance in this stage but his 
influence decreases as the project moves on. After champion, a sponsor has the greatest 
impact since his role is to persuade other people in the organization to perform the 
project. A gatekeeper has the highest ranking of importance at the end since he sets the 
specific criteria to decide whether to accept the development of ideas into the formal 
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development. Furthermore, Markham et al. (2010) argued that these activities do not 
necessarily need to be performed linearly; however each step must be dealt with before 
the project enters the formal development stage. 
 
 
Figure ‎2.8. Model of roles and activities over the FFE process (Markham et al., 2010) 
 
2.3.2.3. A causal model 
Parallel to the studies approaching the FFE from a theoretical consideration, Zhang 
and Doll (2001) proposed a model in order to find the relationship among FFE, 
foundation elements, team vision and success of NPD. Their proposed model is 
demonstrated in Figure 2.9. They mentioned that the meaning of the FFE, derived from 
the term ―front-end fuzziness‖, was still vague, and imprecise. Fuzziness was often used 
in a very broad sense, and hence could refer to both the exogenous causes (like 
environmental uncertainty) and the internal consequences (like the team vision). 
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Otherwise, it was mentioned that no researchers had studied the FFE separately from the 
consequences of fuzziness. The authors identified that the important factors in their 
model are the foundation elements, environmental uncertainty and team vision. This 
model could help researchers with managing the fuzzy front of NDP by separating the 
FFE and unclear team vision. 
 
Figure ‎2.9 The fuzzy front end and success of new product development model. (Zhang and Doll, 
2001) 
 
The model is a conceptual framework which could suggest the relationship among 
front-end fuzziness, foundation elements, team vision, and success of NDP as follows: 
 
1) The front-end fuzziness has negative effects on the success of NDP  
The uncertainty related to customers and technology usually results in less rational work 
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in an organization. Customer fuzziness such as the ―uncertainty of demand and 
appropriate product characteristics‖ complicate the NDP. On the other hand, technology 
fuzziness such as the ―uncertainty of design, process functions and manufacturing 
capability‖ brings additional uncertainty about the time to market, product integrity and 
the NDP cost. This fuzziness could result in a less controllable product development. 
 
2) The front-end fuzziness has negative effects on team vision 
The customer, the technology and competitor‘s uncertainties, or the environmental 
fuzziness in general all greatly complicate the activities of a design team. Due to these 
uncertainties, developing the products‘ concept and the projects‘ work plan is difficult for 
the team.  
 
3) Team vision has a positive relation with the success of NDP 
The more information about the needs of current and potential future customers is shared 
among the team members, the better understanding of the product concept can be 
achieved, which, in turn, facilitates the formulation of a customer-focused mission. Such 
shared information makes the project objectives more focused on real customer 
requirements, which consequently results in a greater success of the new product. 
    
4) The front-end fuzziness has positive effects on foundation elements 
In order to cope with the ambiguity and uncertainty of customers, technology and 
competitors, organizations need to develop special mechanisms to avoid, reduce or take 
advantage of the uncertainties. These mechanisms are foundation elements, also called 
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coping mechanisms (Gerwin and Tarondeau, 1982), and include strategic orientation, 
concurrent engineering, heavyweight manager, customer and supplier involvement and 
platform products. Therefore, the environmental uncertainty requires the firm to improve 
its foundation elements and have more flexibility to respond to the fuzziness.  
 
5) The foundation elements have a positive effect on team vision 
The foundation elements could help the firm to avoid the ambiguity. Consequently, it 
could help the team improve its knowledge about customers, technologies and 
competitors, and such shared knowledge in turn improves the team vision. 
 
6) The foundation elements have positive effects on the success of NDP  
The foundation elements improve the productivity and flexibility of a firm, which results 
in a more valuable product, low cost manufacturing and less time to market delay. 
Customer orientation makes the product more valuable to customer while technology 
orientation reduces the cost of manufacturing. Competitor orientation helps in decreasing 
the time to market period and heavyweight manager reduces engineering change time and 
improves the productivity. 
 
2.3.2.4. Strategic and operative levels of FFE 
Along with a few articles which address both the strategic and operative level of FFE 
(Zhang and Doll, 2001; Khurana and Rosenthal, 1997), Poskela et al. (2005) created a 
holistic view of the front end phase by considering both aspects at the same time. The 
main feature of their model is a clear distinction between the strategic level and the 
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operative level of the front end activities. In this study, a considerable effort was made to 
examine the integration mechanism of these two levels and to analyze the challenges how 
they are perceived by managers.  
Poskela et al. (2005) proposed that there is no best way for the effective integration 
of strategic and operative level front end activities, and the best practices should thus be 
modified based on the type of a certain industry. This also agrees with the studies of Loch 
(2000) and Tidd (2001) who had previously presented similar conclusions. 
 
2.3.3. Summary of early phase process models 
Table 1 compares the nature, research methods and the key findings of the 
previously described process models. 
 
Table 1. Studies on the early stage of innovation process 





single case study  
Defined a framework to 
show the important and 
crucial factors of fuzzy 
front end by considering 
both market pull and 





framework for fuzzy front 
end to be used by German 
software industry 
Koen et al. 
(2001) 
A group effort of 





each element of 
the proposed 
model (NCD) 
There was no common 
language or definition for 
the FFE. Therefore, a 
theoretical construct was 






- Theoretical construct 
- There is a strong 
correlation between 
the proficiency of the 
front end of 
innovation  in a 








study of fuzzy 
front end 
activities in 11 
companies by 
Introducing a system view 
of fuzzy front end to help 
companies in the way they 
manage the front end 





- Introducing front end 
stages  
- Having a system 
perspective to 





followed by conducting 
case studies to identify 
challenges and solutions. 
process 
- There is no one 
solution for front end 













Considering both the 
strategic level and 
operative level of FFE and 
analyzing how these two 













- Top down strategy 
formulation and 
implementation 






They try to make a better 
understanding of front end 
fuzziness which is broadly 
identified as environmental 
uncertainties. However, by 
presenting a theoretical 
framework they try to 
make a distinction between 
the exogenous cause and 
internal consequences of 
fuzziness. 
 The conceptual model 
reveals that: 
- The front end 
fuzziness has negative 
effects on the success 
of NDP and on team 
vision. 
- Team vision has 
positive relation with 
the success of NPD  
- The front end 
fuzziness has positive 
effects on foundation 
elements. 
- The foundation 
elements have 
positive effect on 
team vision and on the 





of NPD and 
innovation 
management 
The goal of this study was 
to clarify the nature of 
front end process of radical 
innovation and to develop 
a model in this regard. In 
their model, three 
perspectives about 
innovation were jointly 
applied. 
 - Three different 
interfaces of front end 
process were 
identified 
- A model of the front 
end in terms of the 
proposed interfaces 
was presented 
- Then, the nature of 
fuzzy front end was 
introduced by 
developing 



















Identifying the activities 
and roles constructing the 
gap between two well 
known stages of 
innovation, i.e. research 
and formal NPD which is 
addressed here by Valley 
of Death 
 - Different roles of 
front end activities 
were introduced. 
- Champion to identify 
and advocate new 
ideas. Sponsor to 
persuade other people 
in the organization to 
perform the project. A 
gatekeeper to 
establish specific 
criteria to decide 
whether the ideas go 






2.4. Innovation process in biotechnology industry 
As demonstrated, reviewing extant literature reveals various process models of the 
early stage of innovation that provide a firm with a better understanding of the activities 
and roles involved in the early stage of innovation. They also offer a framework based on 
which firms can assess their processes according to the best practices. However, the 
application of these models has been limited to investigating the innovation processes 
within the traditional industries that mainly introduce incremental innovation, while the 
biotechnology industry has been overlooked. Therefore, further evaluation is required to 
extend the understanding of the early phase of innovation beyond the traditional field of 
inquiry. 
In the current economic climate, the importance of technological innovations is more 
apparent for the high-tech industries, such as biotechnology, whose sustainability in the 
market highly depends on introducing new technologies (Hall and Baghchi-Sen, 2002; 
Afuah, 2002; García-Muiña et al., 2009).  The biotechnology industry is generally 
composed of biotechnology firms, research institutes and related industrial firms. These 
related industries include agriculture, computer, medical devices, pharmaceutical, 
chemical and environmental industries (Hall and Baghchi-Sen, 2007).  
Biotechnology is considered to be one of the vital growth areas for the emerging 
knowledge economy. Biotechnology has a high ability to shape the way we live by 
improving human health and quality of life (Gans and Stern, 2004). The increasing 
number of diverse biotechnology firms in Canada makes the innovation a critical factor 
for firm survival. This has resulted in an increased interest in the innovation process in 
the past few years.  
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There are particular characteristics of innovation in biotechnology, which makes it 
quite distinct from other technologies. Todtling and Trippl (2007) used the concept of 
―knowledge base‖ to obtain a better understanding of these differences, as presented in 
Table 2. 
 
Table 2: Synthetic and analytical knowledge base (Todtling and Trippl, 2007)  
Key features 
Synthetic knowledge base 
Traditional industries (e.g. industrial 
machinery, engineering) 
Analytical knowledge base 
Knowledge based industries (e.g. 
biotechnology, ICT) 
 Dominance of tacit knowledge and 
practical skills 
 
 Dominance of codified (codifiable) 
knowledge, complementary role of tacit 
knowledge  
 Application or novel combination of 
existing knowledge 
 
 Application of widely shared and 
understood scientific principles and 
methods 
 Low level of R&D 
 
 Systematic basic and applied research , 
formally organized knowledge processes 
(e.g. in R&D departments) 
 Strong orientation on solving specific 
problems articulated by customers 
 Strong reliance on scientific research 
inputs from universities, government labs 
and other research institutions 
 Learning by doing and interacting, user-
producer relationship 
 Learning by exploring, university-industry 
partnerships 
 Incremental innovation  Radical innovation 
 
Biotechnology is very science-intensive and largely uses abstract and codified 
knowledge (Todtling and Trippl, 2007). Considering the generation of sustainable 
competitive advantage, tacit knowledge is also necessary for successful innovation in 
biotechnology industry (Oliver, 2003; Khilji et al., 2006). In addition, the knowledge 
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base of biotechnology is very complex and sources of knowledge are broadly dispersed 
(Todtling and Trippl, 2007). Making alliances with other biotechnology firms, university 
research institutions and all other external knowledge sources, played an important role in 
providing biotechnology companies with faster access to knowledge and a quick reaction 
to any changes. The innovation process in biotechnology is characterized by high R&D 
cost, global competition, rapid changes, long development time as well as considerable 
degree of uncertainties. On average, as shown in Figure 2.10 the entire biotechnology 
innovation process can take 15 years (Khilji et al., 2006).  
 
 
Figure ‎2.10 A drug process in biotechnology (Khilji et al., 2006) 
Innovation process in biotechnology generally has been presented by a sequence of 
activities that transform an idea into a commercial product (Hall and Baghchi-Sen, 2002). 
However, various sources of literature demonstrate many differences in defining and 
naming of the stages in different models. According to Heinonen (2009), product 
development process in biopharmaceutical industry has two main stages: discovery and 
development. The innovation process starts with the discovery of new molecules, which 
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ultimately leads to the filing of patents. In the development stage, preclinical and clinical 
developments are carried out.  
Khilji et al. (2006) claimed that innovation process comprises of two main stages, 
prediscovery and postdiscovery. Prediscovery stage, or stage of invention, consists of 
basic research and R&D activities, whereas in the postdiscovery stage, a tangible 
commercial product is finally achieved. Their representation of the biotechnology 
innovation process is shown in Figure 2.11.  
 
 
Figure ‎2.11 Biotechnology innovation process (Khilji et al., 2006) 
Hall and Baghchi-Sen (2007) also defined the innovation process in biotechnology in 
two main stages: earlier stage and later stage. Earlier stage is characterized by heavy 
R&D, and leads to patent application and approval, while later stage includes 
commercialization of product and process and finally leads to the creation of a new or 
redesigned product or process. 
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However, Van Moorsel et al. (2007) considered four stages for new biotechnology 
product development after the idea generation stage. It could be implied from their paper 
that the authors assumed that an idea is first generated by public sectors and then it 
reaches the firm. As it is illustrated in Figure 2.12, these four stages are: firm-level R&D, 
clinical testing or field trial, regulatory phase and finally market development stage. They 
also grouped these four stages into two phases: early focus (stages one and two) and late 
focus (stages three and four).  
 
 
Figure ‎2.12 Biotechnology development process (Van Moorsel et al., 2007) 
As seen, the use of the term ―front end of innovation‖ in the scientific literature 
related to biotechnology innovation is rare or nonexistent. This stage of innovation was 
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typically addressed by the terms of the discovery stage or early stage. Despite ever 
growing body of literature on the innovation process in biotechnology, there are only 
very few studies about the nature of the early stage in the innovation process. 
Hall and Baghchi-Sen (2002) and Khilji et al. (2006) argued that the linear 
representation of the innovation process in biotechnology is inappropriate, since it cannot 
demonstrate feedback mechanism and interaction of various elements in the process. 
Especially the actual early stage of the innovation process is more iterative and complex: 
in house research together with external collaboration provides a knowledge source for 
generating new ideas. These two sources complement each other rather than being 
substitute (Arora and Gambardella, 1994; Valle and Gambardela, 1993). The amount of 
information absorbed by the firm from external collaboration is also related to its own 
level of knowledge and capabilities. Although the biotechnology industry is well known 
for making frequent collaboration agreements, establishing the collaboration in the 
discovery stage is difficult (Khilji et al., 2006). Nevertheless, companies with high level 
of internal knowledge have better potential opportunity to get involved in collaboration 
relationships with other partners (Arora and Gambardella, 1994; Hall and Baghchi-Sen, 
2007).  
The various described interactions among different elements of the innovation 
process reflect the inherent complexity of this process. In order to understand the 
behaviour of this complex system, an in-depth investigation of these factors and the 
relationships among them is required. In this regard the following part reports the critical 
elements of the early stage of innovation process in biotechnology. 
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As it was stated earlier, only few studies have been conducted to examine the 
relationships and feedbacks among the factors comprising the early stage of the 
innovation process, particularly in the context of high-technology industries. Existing 
studies are mostly based on a mixed set of industries or on a traditional industry, but 
biotechnology is rarely considered (Khilji et al., 2006). Given the importance of 
biotechnology for Canada and the mentioned lack of research in this field, further 
research work is needed to investigate the innovation process in biotechnology, and this 
is also the general objective of this thesis. 
 
2.5. Significant elements of the early stage of innovation in biotechnology 
2.5.1.  Sources of knowledge 
Innovation in biotechnology is a result of research and development activities and 
other kind of learning activities that are usually undertaken with the aim of acquiring a 
new product (Marsh and Oxley, 2005). Product introductions in biotechnology are mainly 
initiated by scientific breakthroughs in the laboratory, while the market need is the 
principal driving force for further development and commercialization of the product 
(Hall and Baghchi-Sen, 2002). Therefore, acquiring knowledge has a great role in the 
search process for an innovation (Nelson, 1982). 
The resource-based view of the firm (RBV) suggests that a firm‘s resources and 
capabilities are critical for surviving in the market place (Penrose, 1959; Barney, 1991).  
Many scholars (Kogut and Zander, 1992; Petraff, 1993; Henderson and Cockburn, 1994; 
Hill and Deeds, 1996; Deeds et al., 1997) emphasized that intangible resources, such as 
knowledge, play a key role in maintaining a firm‘s competitive advantage. Several 
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studies in the strategy literature claimed that a variation in a firm‘s performance is highly 
dependent on the resources or capabilities of the firm, especially when these capabilities 
are impossible or difficult to imitate or trade (Cockburn et al., 2000; Teece et al., 1997). 
Since biotechnology is highly research-intensive, the competitive advantage strongly 
depends on the continuous accumulation of relevant knowledge.  In this regard, the fast 
creation of knowledge and the way how to manage it have been the focus of research for 
firms and region success (Dangelico et al., 2010).  One of the fundamental questions in 
the strategy field pertains to how this resource can be created, maintained and enhanced. 
The sources of technological knowledge can refer to the tools that firms can utilize to 
accumulate knowledge in order to exploit it with an aim to  introduce innovative products 
or processes (Garcia-Muina et al,. 2009).  
Many scholars (Malerba, 1992; Zahra and Nielsen, 2002; Garcia-Muina et al., 2009; 
Hu and Hsu, 2008; Dangelico et al., 2010) argued that new knowledge can be generated 
by two alternative means: the firm‘s own R&D (internal sources) at one extreme, and the 
acquisition of knowledge in competitive markets and the interorganizational linkage 
(external sources) at the other. Internal sources can be defined as all the methods for 
accumulating knowledge through the firm‘s own learning processes, such as conducting 
internal research and development activities (R&D) and the experience acquired by 
performing organizational process and studying via research projects (Nieto Antolin, 
2001) .  
External sources can refer to any type of accumulation and incorporation of 
technological knowledge in which a third party is involved. The direct purchase of 
technology, technology incorporated in machinery required, licensing contract, 
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university-industry linkages and relationships among firms are examples of external 
knowledge (Todtling and Trippl, 2007; Garcia-Muina et al., 2009). In fact, the external 
learning process involves learning by imitation and learning by interaction (Dangelico et 
al., 2010). Learning by interaction refers to the continuous exchange of information 
among firms, firms and research organizations, and firms and customers. On the other 
hand, learning by imitation is based on a one-side exchange of knowledge among 
innovative actors, which can be obtained by consultation of scientific and technical 
publications, as well as participation at events such as conferences and trade fairs 
(Dangelico et al., 2010). 
Early research about the internal source of knowledge (Beer, 1959), later supported  
by another scholar (Garcia-Muina et al., 2009) reveals that this knowledge has a greater 
strategic value compared to external knowledge. Internal source of knowledge provides 
firms with breakthrough innovations that can create competitive advantages for them, 
since it prevents other firms from imitating a firm‘s distinctive capabilities. This could be 
justified by the characteristic of this type of knowledge due to its tacitness and specificity 
(Matusik, 2002; McEvily and Chakravarthy, 2002; Schroeder et al., 2002, Garcia-Muina 
et al., 2009). The term 'tacit knowledge' refers to the knowledge which could not be 
easily expressed, shared, and transferred by means of language.  
Despite the obvious benefits of employing internal sources of knowledge, there are 
some drawbacks involved. The innovative process associated with these types of 
knowledge is more iterative, time consuming, and expensive, and firms are faced with 
greater uncertainties and risks. External sources of knowledge, on the contrary, are 
cheaper and less risky, but at the same time, the external knowledge cannot generate a 
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competitive advantage on its own, since it is easily available to rivals (Garcia-Muina et 
al., 2009). However, in biotechnology, which is characterized by rapid and complex 
technological change, it is hard to find all the necessary competencies needed to innovate 
under a single roof. Hence, the companies cannot rely only on internal source of 
knowledge (Shan and Song, 1997).  
In this regard, making strategic alliances and other collaborative agreements among 
universities and other biotechnology and pharmaceutical firms are well-accepted strategy 
for achieving innovation (Hall and Baghchi-Sen, 2002; Coombs and Deeds, 2000). A 
strategic alliance is a partnership that incorporates resources and core competences for 
achieving similar goals (Hitt et al., 2007). Making collaborations allows individual firms 
to advance their scientific discoveries when there is a lack of specific resources or 
expertise. However, a significant strategic commitment to R&D is critical for a 
knowledge intensive technology, such as biotechnology, in order to achieve the 
competencies required to succeed, despite the level of technology developed in-house or 
accessed through external resources. 
 
2.5.2. Absorptive capacity  
The increasing number of firm-university linkages raises the question of whether 
firms can improve their ability to use and exploit such knowledge. Even though the 
external knowledge is easily available to competitors, the firms cannot gain benefit from 
it equally. The concept of absorptive capacity brings attention to the fact that when 
knowledge exists outside of the firm, even if it is in public domain, it cannot be 
effortlessly and freely absorbed by all the firms.  Instead, investing in particular activities, 
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such as research and distinctive capability is required to allow firms to identify, 
assimilate, transform and exploit outside knowledge more effectively (Cohen and 
Levinthal, 1990).  
The level of a firm‘s prior knowledge allows the firm to recognize valuable new 
information, absorb it and incorporate it into creating new knowledge.  A firm has a high 
absorptive capacity to process new information and ideas when they have a well-
developed foundation of knowledge in that field. On the contrary, when the knowledge 
level of the firm is low for a particular field, it will not be able to recognize new valuable 
knowledge and exploit the new information that might be important for their product 
(Deeds, 2001).  In competence-based technologies, such as biotechnology, the ability of 
the firm to recognize valuable knowledge that may be useful for them in the future is vital 
for the firm‘s success (Deeds, 2001). 
Several activities have been identified in literature that may contribute to the creation 
of a firm‘s absorptive capacity. Cohen and Levinthal (1990) considered R&D 
investments as an important factor to their conceptualization of absorptive capacity. They 
have regarded R&D as both a source of innovation and a mean for developing the firm‘s 
ability to recognize new, external knowledge. The firm‘s basic research (Rosenberg, 
1990; Lane & Lubatkin, 1998), the routines of a firm (Zahra and George, 2002), 
employee skills (Vinding, 2006; Muscio, 2007), collaboration with an external scientist 
(Cockburn and Henderson, 1998; Zucker et al., 1998), technological overlaps (Mowery et 
al., 1996; Prager and Omenn, 1980), and trust and cultural compatibility among firms  
(Lane et al., 2001) are other activities that can enhance knowledge acquisition 
capabilities of firms and develop absorptive capacity.  
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In fact, absorptive capacity improves the ability of a firm to evaluate the probability 
of success for turning a given basic knowledge into a valuable product. It is more likely 
for a firm with a higher absorptive capacity to pursue projects with a higher probability of 
success. Furthermore, due to their superior knowledge, the firms with a greater absorptive 
capacity can understand any changes in new knowledge faster and can eventually change 
their research efforts more rapidly to adjust to the new information stream. 
 
2.5.3. Funding  
Funding is considered to be a backbone of biotechnology, since firms spend huge 
amount of money on research and development activities (Hall and Baghchi-Sen, 2002). 
The funding can be provided to the biotechnology firm from different investment 
sources. Financing in start-up companies is mainly supplied by government research 
funds and venture capital firms, but firms also search for capital from angel investors, 
government programs and initial public offerings (Shan et al., 1994; Van Moorsel et al., 
2007). However, even though startup companies may have funding to invest on R&D 
activities and early parts of development, they often lack the necessary testing facilities 
and equipment for further development and commercialization of a product.  It is really 
difficult for biotechnology firms to attract venture capital market to carry them through 
the entire innovation process. The reason is that capital markets are mostly focused on 
short term results, which usually cannot be gained by the investment in biotechnology 
innovations. The long term development process, as well as regulatory processes, may 
significantly slow down the progress of a product in the development pipeline. 
Consequently, a firm has to combine different sources of funding such as public funds, 
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venture capitals and debt financing to survive its operations (Greis et al., 1995; Hall and 
Baghchi-Sen, 2002). Nevertheless, the amount of investment in R&D differs based on a 
firm‘s commitment to research and development activities. This is represented in the 
literature by R&D intensity, defined as the percentage of a firm‘s revenues spent on 
research and development (Hall and Baghchi-Sen, 2007).  High R&D intensity firms are 
mainly characterized by low revenue and focus more on the earlier stages of innovation, 
which usually involve heavy R&D investments and access to university research. Low 
R&D intensity firms mostly focus on the later stage of the innovation process, which 
includes commercialization of the product or process (Hall and Baghchi-Sen, 2007).  
Commitment to research and development activities, using external knowledge, 
making alliances with major research institutes, a supply of skilled scientists, access to 
venture capital and government support are all critical factors for the achievement of a 
successful innovation process. Although each aspect is individually significant, their 
combined utilization creates a complex system that can be hardly controlled without 
having planned strategies. In this regard, managers and policy makers need to know how 
these factors affect each other, and which strategies improve firm performances the most 
under different conditions. 
 
2.6. The purpose and questions of the research  
The importance of innovation for biotechnology firms and its role in providing the 
firm with capabilities that are essential for its success underscore the need to understand 
the structure and nature of the biotechnology innovation process. In this thesis, the main 
research questions are related to this process:  How are innovations created in research-
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driven high technology firms such as biotechnology, and what are the key determinants 
of the successful innovation process?  What roles do these factors play in the innovation 
process? How can they affect the innovation output in the biotechnology? Where should 
these firms focus their efforts and resources in order to enhance their innovation outcome, 
while taking into account their characteristics and limitations? These are interesting 
issues that have significant implications for the policy makers and managers of 
biotechnology firms. 
Despite the extensive body of knowledge within the determinants and the effects of 
successful innovations, there is still a lack of research and information elucidating the 
dynamic nature of policy decisions and feedback mechanisms of innovation process. In 
this regard, this research intends to supplement the literature by investigating the factors 
that enhance innovation performance in biotechnology during the research stage. In doing 
so, our two main objectives are: 
 
Objective 1: Contribute to a better understanding of the early stages of the 
innovation process in biotechnology  
 Develop a comprehensive model that represents the relationships and 
interactions among several identified factors 
 Use the model to investigate the behavior of a firm under various conditions 
and to determine its best innovation strategies. This can provide managers 
with important information about factors that have an effect on the outcome of 
the early stage of the innovation process  
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 Supply policy makers with a tool which will help them identify the most 
significant issues in policy making for facilitating the whole organization‘s 
growth through the innovation process 
 
Objective 2: Investigate the effects of various policies regarding different sources of 
knowledge on the innovation process outcome 
 Determine the appropriate policies in proportion to the firm‘s characteristics 
in order to pursue their innovation goals that can serve as recommendations 
for policy makers 
 Provide insight about the effects of various sources of knowledge on the 
firm‘s expected innovative plan 




Chapter 3  
3. System dynamics methodology 
3.1. The relevance of system dynamics method to the research topic 
In the context of biotechnology, a new established firm is faced with an environment 
where many large and small companies are competing with each other to develop a new 
product (Deeds, 2001). In most cases, these firms only have a few tangible assets and 
required talent and skills to compete with other firms. The only way they can compete 
and maintain their position is with their research capabilities.  
In this regard, firms should identify different technological policies in order to 
improve their scientific and technological capabilities. Given the limited resources and 
numerous investments of a high technology company, the manager needs to make a 
critical decision about how to reasonably allocate these resources, including human 
resources and funding (Deeds, 2001). Investing in internal R&D activities and utilizing 
external sources are two important sources of acquiring new knowledge that a firm 
should invest in. However, each of the strategies has its own characteristics. Therefore, it 
is required for the manager of a biotechnology company to determine the levels of 
investment in each of these areas to maximize the performance of the company.   
The decision of how to exploit different sources of information for creating 
innovation resources is not a static decision. To maintain a competitive advantage, a 
biotech firm must constantly review their previous decisions on the allocation of 
resources to timely react to any changes. A firm also needs to identify different strategies 
in order to respond to a variety of internal and external conditions. While analytical 
models in biotechnology innovation (Van Moorsel et al., 2007; Traore, 2004; Kang and 
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Lee, 2008) provide valuable insights into potential factors and drivers contributing to the 
creation of new knowledge and innovation, they do not provide a temporal understanding 
of the dynamic nature of policy decisions and feedback mechanisms.  
In the literature, system dynamics modeling is suggested as a possible methodology 
to capture this dynamic decision process because of the methodology's ability to deal 
with both quantitative and qualitative variables and the existence of a supportive 
computer-based modeling package (Galanakis, 2006; Dangelico et al., 2010; Garcia et 
al., 2003).  Several authors have used a system dynamics methodology to analyze 
specific problems related to decision making in the technological innovation process 
(Garcia et al., 2003; Galanakis, 2006; Lin et al., 2006; Dangelico et al., 2010; Wu et al., 
2010). 
For example, Dangelico et al., (2010) utilize system dynamics modeling to 
investigate the influence of knowledge and proximity dimensions (geographical, 
cognitive and organizational) on the firms‘ decision on whether to join a technological 
district. Their analysis shows that the amount of knowledge spillovers and the level of 
proximity dimensions affect the number of outgoing and ingoing firms on a dynamic 
basis with respect to time. Knowledge spillovers are defined by Griliches (1979) as 
―working on similar things and hence benefiting much from each other‘s research‖ 
(quoted in Feldman, 1999, p.7). Similarly with system dynamics, the behavior of the 
agglomeration process in a technological district is justified through explaining some of 
the fundamental reinforcing and balancing loops (Dangelico et al., 2010). 
In this research, a system dynamics simulation model of the early stage of innovation 
in biotechnology is developed to gain a better understanding of the dynamic behavior of 
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this complex system. Different scenarios are created and tested with system dynamics 
modeling to explore managerial implications of decisions regarding the extent of 
developing knowledge internally or acquiring external knowledge over time. 
The existing system dynamics models of the innovation process focuses on the 
general aspects of innovation and only provides an overall understanding of the different 
factors that form an innovation system (Galanakis, 2006). The work of Garcia et al., 
(2003) is the only one that employs system dynamics modeling for investigating different 
innovation policies, but their study was not designed specifically for biotechnology. 
Using system dynamics allows us to achieve our twofold purpose. First, we 
contribute to the understanding of factors affecting the earlier stages of the innovation 
process in biotechnology, as well as developing a comprehensive model that represents 
the interactions among identified factors for innovation creation, resource allocations, and 
feedback mechanisms over time. Secondly, system dynamics allows developing a 
simulation model by which we can investigate the effects of different sources of 
knowledge on the innovation process outcome in the early stages of the innovation which 
may help policy makers develop more effective policies in order to satisfy their 
innovative goals. 
  
3.2. The system dynamics methodology  
System dynamics modeling was founded by Forrester (1968) and developed recently 
by Coyle (1996), Maani and Cavana (2000) and Sterman (2000). It maps the decision-
making process, operating polices and information flow in an organization by combining 
information feedback theory and behaviour decision theory (Morecroft, 1985; Sterman, 
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1987). System dynamics can also be used to analyze policy decisions and their 
corresponding feedback. Decisions of a firm or a supply chain network usually show the 
dynamic complexity (Forrester, 1968; Morecroft, 1985), which can be very difficult to 
capture in static models. 
 
3.3. Different types of the system’s elements: stocks and flows 
The stocks‘ elements represent an accumulation of measureable items such as the 
age, the total amount of budget, or the whole number of cars within a country.  Stocks are 
not necessarily limited to physical tangible concepts and they may also represent 
intangible items such as the accumulated knowledge of developing patents in the R&D 
department of a firm.  
Flow elements represent the inflow and/or outflow to/from stocks. The role of 
auxiliary variables applies to the model through the flow elements. Policy-making 
scenarios can be applied to the system by controlling the flow elements, initial status of 
stock or auxiliary variables. 
  
3.4. Time Delays 
Time delay is another important aspect for developing system dynamics models 




3.5. The relationship of the system’s element: feedback cycles 
All dynamics of the system take place because of the interactions of just two types of 
feedback loops, positive (or self-reinforcing) and negative (or self-correcting) loops 
(Sterman, 2000). 
In positive loops, a variable constantly feeds upon itself to reinforce its own growth 
or collapse. For example, as shown in Figure 3.1 more chickens result in more eggs laid, 
which will hatch and be added to the chicken population, leading to even more eggs, and 
so on. A Causal Loop Diagram or CLD captures the feedback dependency as it is shown 
in the example of chickens and eggs. The loop identifier R in the center of the loop shows 
that it is a self-reinforcing loop. 
The positive (+) and negative signs (-) on the arrows indicate the relationship 
between the variables in the model. The polarity specifies the influence of the 
independent variable on the dependent one. A positive sign means that by increasing or 
decreasing the independent variable, the dependent one will also increase or decrease, 
respectively. A negative sign indicates an opposite trend, so the dependent variable will 
decrease or increase as the independent variable is increased or decreased, respectively. 
A balancing (also known as self-correcting and virtuous) loop is a loop that restricts 
its own growth (Sterman 2000). The balancing loop or negative loop is a loop that 
exhibits goal-seeking behaviour. The balancing loop changes its value while being 
affected by a variable in the system. The loop obtains an equilibrium state when the goal 
is reached. The S-shape (or logistic) growth curve and the asymptotic growth (decay 
function) are normally assigned to the balancing loops (Sterman 2000). An example of a 
negative loop is shown in Figure 3.2. As the chicken population grows, more road 
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crossings will lead to fewer chickens. More road crossings means that more chickens 
stand the risk of getting hit by a car, hence this leads to fewer chickens. The loop 
identifier B in the center of the loop shows that this is a balancing loop. 
 
Figure ‎3.1 A positive feedback loop (Sterman 2000: 13) 
 
 




4. The model description  
4.1. The description of the causalities: the causal model  
4.1.1. The big picture of causal model  
The aim of this modeling is to better understand the early stage of the innovation 
process in biotechnology companies. The structure of the model includes (a) the 
significant elements that form the whole system of innovation at its early stage and (b) 
the relationships among these elements which underlie the dynamics of the innovation 
process. Regarding the elements of the systems, reviewing the literature illustrates the 
following as the main influential items in the early stage of innovation: the R&D 
activities, external source of knowledge, absorptive capacity and funding components. In 
addition to these elements, another aspect of the structure of the model is the causal 
relationships among these elements. The causal diagrams, as explained in the previous 
chapter, help us to portray the relationships among the identified factors in order to 
illustrate the whole causality of the system. The causal diagram developed in this study 
for the early stage of innovation at the biotechnology firms contains five causal loops: 
knowledge creation, knowledge accusation, capital raising, venture capital investment, 
and R&D lock-in. The following section introduces these five causal loops and their 




4.1.2. The first loop: knowledge creation  
As it was described earlier, knowledge for innovation can be provided by two main 
sources: internal sources and external sources. A firm‘s research and development efforts 
mainly supply internal sources, while external sources can be provided with the 
acquisition of knowledge in competitive markets (Dangelico et al., 2010; Garcia-Muina 
et al,. 2009; Todtling and Trippl, 2007). These relationships are shown in Figure 4.1 the 
positive signs above the arrows indicate that the more R&D effort the firm exerts the 
more profound internal learning, the more it will achieve and the more knowledge is 
created for generating innovation. Also it is shown that the level of knowledge will 
increase with an augmented utilization of external sources. 
 
 
Figure ‎4.1 Sources of knowledge creation 
Once the firm has accumulated knowledge from various sources, the tacitness of 
knowledge needs to be manipulated and altered for developing innovations. The process 
of converting tacit knowledge into messages such as databases, patents, papers, user 










Garcia-Muina et al., 2009). In biotechnology, the firms have a high propensity to patent 
their discoveries because preventing them from duplication and securing royalty income 
is critical for their output (Scherer, 2002). Patents are therefore well-accepted measures 
of innovation, regardless of whether the innovation reaches commercial ends. De Luca et 
al. (2010) claimed that in biotechnology, due to the length and complexity of scientific 
exploration, indicators which are common in traditional industries such as the market 
performance or the number of new products, cannot be fully utilized to describe 
innovation performance. As a result, the accumulation of knowledge results in the 
creation of innovation in terms of patents.  The arrow connecting the ―knowledge for 
innovation‖ and ―the idea generated‖ in Figure 4.2 demonstrates this relationship. 
Eventually, the existing innovative ideas and information of a firm influence the internal 
learning of the firm by both changing the direction of future R&D activities and 
enhancing internal learning from experience gained by creating innovation and 
representing them with patents (Galanakis, 2006; Dangelico et al., 2010). These relations 
lead to creation of our first positive loop, Knowledge creation, represented in Figure 4.2. 
This loop describes that the more a firm carries out research and development, the more 
the internal learning of the firm will be enhanced to ultimately results in the creation of 
new knowledge and innovation. Then, the created innovation will direct the forthcoming 




Figure ‎4.2 Knowledge creation loop 
 
4.1.3. The second loop: knowledge acquisition   
It is very important for the success of a biotechnology firm to consistently keep 
acquiring knowledge from beyond its boundaries (Coombs et al., 1996; Dodgson and 
Rothwell, 1994). Through external sources, the firm is able not only to obtain new 
knowledge that could be directly exploited in various research projects, but it can also 
gain enough new information to constantly re-evaluate its projects‘ portfolio (Deeds, 
2001). However, it has been suggested by Cohen and Levinthal (1990) that the firm 
cannot easily absorb this knowledge without exerting its own effort, i.e. the firm needs to 
invest in building its absorptive capacity.  Absorptive capacity enables the firm to 
recognize and assimilate valuable knowledge, then transform and apply the knowledge to 
















 There are several possible measures of absorptive capacity that are established in the 
literature. Most commonly, ―the amount of R&D investment‖ is recognized as an 
appropriate indicator (Cohen and Levinthal, 1990; Zahra and George, 2002; de Jong and 
Freel, 2010), and has been also proposed for measuring the absorptive capacity among 
small firms (Muscio, 2007). Moreover, the number of qualified scientists is also 
considered an important proxy for measuring the absorptive capacity in small to medium-
sized biotech firms (Muscio, 2007). This is also consistent with the research of Reid and 
de Brentani (2004) in which human attributes, such as perception (quick identification 
and interpretation ability), reconstruction (representation ability) and classification 
(evaluation), allow firms to separate potentially relevant and irrelevant information from 
the environment.  
As Figure 4.3 shows, undertaking more R&D activities as well as more qualified 
scientists working in the firm will provide the company with an improved ability to 
acquire knowledge from external sources, and thus to increase its absorptive capacity. 
These relationships create our second positive loop. This loop is demonstrated by thicker 
arrows in Figure 4.3 as the Knowledge acquisition loop.  This feedback loop expresses 
that conducting more research activities improves the firms‘ ability to absorb and exploit 
external knowledge so that the firm can expand its knowledge level. The developed 
knowledge, in addition to internal knowledge of the firm, provides the basis for 





Figure ‎4.3 Knowledge acquisition loop 
4.1.4. The third and forth loops: capital raising and venture capital investment  
Many researchers emphasized the importance of funding in the success of new 
product development in biotechnology (Hall and Baghchi-Sen, 2002; Pisano, 2006; 
Heinonen, 2009). As it was argued by Heinonen (2009), there is a positive correlation 
between the amount of investment in R&D activities and the number of new products.  
According to Pisano (2006) only a few companies are profitable because while they are 
developing a new product, they are not producing any revenue through commercial 
products due to the long production cycle.   
As mentioned earlier, a biotechnology firm needs to spend millions of dollars on 
research and development activities. Biotechnology companies are usually funded 
through public money, especially in the earlier stages of product development. However, 

























funding is often supplied by the founder or other individuals (Heinonen, 2009). Firms 
also seek capital from sources such as government programs and business angels. 
Searching for venture capital is extremely important for biotechnology companies since 
development projects in this field are characterized by high levels of uncertainties and 
require a significant amount of money. It is estimated that the cost of the development of 
a new drug is from USD 500-800 million, roughly 40% of which is shared for discovery 
and preclinical studies.  (Tollman et al., 2001; Bains, 2004; Dickson and Gagnon, 2004). 
The total development time is on average between 12 to 15 years for a new drug to be 
discovered and go though pre-clinical and clinical trials to get finally approved (Amir-
Aslani and Negassi, 2006; Khilji et al, 2006). The long development process can be 
justified by the rising number of clinical trials that need to be conducted before the 
approval is granted. It is only after this process that some revenue can be gained.  
Figure 4.4 demonstrates the different sources of financing as well as their 
relationships with other elements of the innovation process. As shown in Figure 4.4, their 
relations form our third positive loop, which is Capital raising. This loop represents that 
the government, private sectors and venture capital are the main sources of financing. 
However, by investing more money in R&D activities, the firm can spend more on 
conducting research which leads to an increase of ideas generated by a firm. 
Besides acquiring funding from public resources, a firm can generate revenue by 
selling or licensing its intellectual property (IP) (Van Moorsel et al., 2007).  Some firms 
only focus their efforts on development activities with the intention of granting or selling 
their IP instead of bringing a product into commercial ends. Intellectual property transfer 
through sale of patents, licensing agreements or material user agreements provides 
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opportunities for networks to share their resources as well. As a firm generates more 
innovations in terms of patents, it can sell or license more of its intellectual properties and 
more money becomes available to spend on R&D activities, thus creating a reinforcing 
loop labelled by Capital raising. As a result, the firm can conduct more research to create 
novel technology and generate more money, although the rise in the number patents can 
directly affect the intention of private sector for investing in novel technology.  
In addition, Niosi (2000) suggests that patents are highly important for 
biotechnological companies, since they act as a signal for venture capital investors 
indicating a unique and valuable technology. A firm with an accumulated higher number 
of patents thus has a better chance to attract the investors. The positive arrow between the 





Figure ‎4.4 Capital raising loop 
4.1.5. The effect of firm size   
Firm size is measured in biotechnology in terms of both funding and available 
resources and has a great effect on the firm‘s capacity to innovate. The firm size can also 
be defined by the number of available employees. The entrepreneurial nature of small 














































because of their bureaucratic nature.  This suggests that medium sized firms (50-150 
employees) have the most effective innovative activities by having  more resources than 
small firms and less bureaucracy than large firms (Van Moorsel et al., 2007). 
Large, integrated high-technology firms mainly take part in all levels of the 
innovation process, which consists of basic research, product development, and finally 
commercialization. Smaller high-technology firms designate themselves as a product 
developer between universities that perform basic research and establish companies, in 
order to enhance their commercialization capacity. The biotechnology in Canada is 
dominated by small and medium sized firms (SME) that devote much of their operations 
to research and development (Hall and Baghchi-Sen, 2002). 
The number of employees in the R&D activities also has an impact on the creative 
capacity at the R&D stage. Traore (2004) empirically demonstrated that a 10% increase 
in the number of biotech R&D employees raises creative capacity by 30%. Hence, as it is 
shown in Figure 4.5, the firm size impacts both the venture capital source of funding and 
the resources available for R&D activities. It affects them positively since by increasing 
or decreasing the size of firm, the amount of venture capital will increase or decrease 
respectively. Similarly, firms have fewer resources and employees for performing 




Figure ‎4.5 Firm size effect 
4.1.6. The fifth loop:  R&D lock-in 
The previously described ―knowledge creation loop‖ and ―knowledge acquisition 
loop‖ represent how higher levels of R&D effort will lead to the creation of more 
innovations. However, this relationship is not always viable and will eventually cause a 
reverse effect on the innovation outcome (Kang and Lee, 2008).  More investments on 




















































form of an inverted U shape, probably because of financial constraints for biotechnology 
(Arvanitis, 1997).  According to Khilji et al., (2006), most available funds are dedicated 
to R&D activities during the discovery stage.  Since private sectors are not interested in 
investing in the research projects during the discovery stage due to the lack of 
commercial products during this stage, high uncertainties and an expected long period 
before the revenue generation.  This in turn has an effect on the total available funds and 
the R&D available funds. Hall and Baghchi- Sen (2002; 2007) also claim that spending 
more on R&D because of too many regulatory procedures and financial constraints slows 
down the recognition of commercial output. Therefore, the unintended effect of 
performing too many R&D activities and dedicating most of the available funds to them 
creates a balancing loop, labelled by a R&D lock-in. 
Figure 4.6 represents this loop, in which more investment in R&D activities over 
time leads to the decline in the number of commercial products. This decrease in products 
means that less private investors are willing to invest in research and development 
activities. Ultimately, because of the decline in one important source of revenue, the 



































































4.2. Formalizing the model for a computer simulation  
Since the modeling process is an iterative process, which consists of formulating and 
testing the hypothesis, the equations and functions of the interrelationships are defined 
and the causal diagrams are transformed into a fully formalized model through a system 
dynamics software package, Vensim. The following causal diagrams, in addition to 
demonstrating important factors identified in the previous section, represent various 
conditions that reflect a firm‘s decision to use a particular source of knowledge. The 
simulation model and equations are also built based on these causal diagrams.  
From the causal models developed in the previous section, it can be concluded that a 
firm can either create all of its knowledge and resource requirements through internal 
R&D activities or utilize external resources, such as creating strategic alliances and 
acquiring knowledge from external parties. Nevertheless, obtaining external knowledge 
and exploiting it to generate new knowledge largely depends on the ability of a firm to 
recognize and develop external resources. This ability highlights a very important aspect 
of organizational learning, defined as absorptive capacity. Absorptive capacity can be 
generated through R&D activities, directly through staff training, or can be developed as 
a by-product of a firm‘s manufacturing operations (Muscio, 2007). 
 
4.2.1. Performance gap 
In this model, the critical decision of when and to what extent the knowledge should 




PG (t) = (target knowledge value- actual knowledge value) (4-1) 
The choice of this measure is consistent with the study conducted by Garcia et al. 
(2003). However, the performance measure used in this thesis is not based on financial 
performance indicators, such as the return on assets, sales growth or profit margin. These 
are inappropriate because biotechnology firms do not have any history of profits or 
earnings due to the long production cycle and the inherent complexity of scientific 
explorations (De Luca et al., 2010).  
Instead, the biotechnology firms‘ value is constrained by intangible assets that the 
firms possess, and these are represented by their knowledge. Therefore, the performance 
measure is defined by the value of knowledge created in the firm. It is assumed that the 
firm sets a performance target for the amount of knowledge it is planning to create. The 
knowledge created by either source of information, i.e. internal or external, produces 
distinct values for the firm. Knowledge that is created by internal learning involves more 
uncertainties and is riskier compared to information that can be achieved through external 
learning (Garcia-Muina et al., 2009). Nevertheless, knowledge and resources acquired 
internally are more likely to provide the firm with breakthrough innovations that can lead 
to the creation of a competitive advantage for the firm (Matusik, 2002; Schroeder et al., 
2002, Garcia-Muina et al., 2009). 
A zero performance gap indicates that the actual performance of a firm is equal to 
the anticipated target performance. In this situation, it is assumed that a firm equally 
focuses on internal research and external resources. A positive gap indicates that the firm 




4.2.2. The role of external resources  
Knowledge acquisition and partnership has been viewed by many scholars as a well-
known strategy to deal with challenges faced by biotechnology companies involving drug 
discovery (Greis et al., 1995; Edwards et al., 2003; Amir-Aslani and Negassi, 2006). This 
strategy helps biotechnology companies to achieve more efficiency in their research and 
development activities in order to improve their performance goals. Major 
pharmaceutical companies have a strong desire to tap into external strategies because 
they provide them with rapid access to both intellectual property and capability (Amir-
Aslani and Negassi, 2006). 
Recent research has suggested that barriers that impede a successful innovation 
process are the primary motivation for companies to pursue the acquisition of knowledge 
from outside of the company (Greis et al., 1995; Amir-Aslani and Negassi, 2006). Amir-
Aslani and Negassi, (2006) argued that the growing R&D costs, increasing development 
time frames, the decrease in productivity, the increase in investor expectations, and the 
need for a new paradigm for drug development are all challenges that pharmaceutical 
companies encounter during drug discovery. In the past, pharmaceutical companies have 
had the time to develop competencies, but due to the increasing expectations of the 
investors and the intensifying competitiveness of the market, they no longer have this 
luxury. Hence, outsourcing R&D efforts and knowledge acquisition have been considered 
as a new strategy to speed up the drug development process. 
In this model, it is assumed that when the gap is positive, i.e. the knowledge level of 
the firm falls behind its target, the company will try to close the performance gap with a 
fast and less risky alternative source of knowledge, which is external knowledge. The 
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positive performance gap can be created by an increase in the expectation of a firm either 
due to internal reasons or from the pressure of competitive environments. This 
assumption is made since it is empirically proved that external knowledge gained through 
collaboration, will benefit firms by providing faster results than if the firms get engaged 
in internal basic research instead (Fabrizio, 2009).   
Amir-Aslani and Negassi (2006) argued that one of the few shared goals that 
biotechnology and pharmaceutical companies have is to bring new drugs into the market. 
Structuring strategic alliances provides them with a less costly, more certain, and more 
flexible way to acquire capabilities that they do not possess. The primary motivation 
behind entering alliances differs such that biotechnology companies desire to share risks 
and to access financial resources, whereas pharmaceutical companies intend to fill the 
gaps in their research pipelines. Hadjimanolis (1999) also argues that small firms use 
external expertise for innovation because of their lack of internal resources.  
The competitive environment forces a firm to set higher goals in order to keep its 
competitive advantage. However, low productivity, high development time, the rising 
costs of R&D activities and the shortening of the product life cycle hinder their ability to 
develop new products on their own. Therefore, it is believed that mergers and 
acquisitions are a substitute strategy for increasing market demands and the immediate 
need for earning.   
After considering the described dynamics of the system, it can be implied that when 
a firm falls behind its target knowledge, it will invest more in acquisition and partnership 
activities that can provide it with external knowledge to decrease the gap between the 
actual knowledge and the target knowledge. Consequently, the decision whether to invest 
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in R&D activities or to make more strategic alliances is made based on the value of 
performance gap. 
The discussed relationships create our first balancing loop which is called B1 (see 
Figure 4.7). This loop reflects that a more positive gap leads to the firm concentrating 
more on external projects. This focus on external knowledge acquisition will result in the 
greater knowledge stock, which finally leads to the decrease in the gap between the target 
value of knowledge and the actual performance of the firm. However, making 
collaborative contracts depends on having sufficient absorptive capacity as well. 
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The first reinforcing loop is demonstrated in Figure 4.8 as R1. This loop demonstrates 
that if the firm exceeds its target then the performance gap is negative and the firm will 
concentrate on the internal R&D activities to introduce a newer and better product in 
order to create or maintain its competitive advantage among the other firms. Unlike in the 
case of the positive gap, the negative gap represents a situation where the firm has 
already achieved its goal, and thus there is no need to concentrate more on external 
knowledge. In this research, it is suggested that firms that achieve their desired 
performance should take the opportunity to focus on internal R&D activities. This allows 
them not only to generate new knowledge, but also to simultaneously enhance their 
ability to absorb and exploit existing knowledge in order to sustain their competitive 
































Figure ‎4.8 The first reinforcing loop R1 
4.2.3. Allocation decision  
In the simulation model, these relationships lead us to the conclusion that the fraction 
of investment on R&D activities or on external knowledge, Indicated Fraction (IF), is 
identified as a function of the performance gap. This variable, which has a value between 
0 and 1, represents the ratio of external source of knowledge to internal source of 
knowledge. When the performance gap is zero, an equal amount of funding will be 
dedicated to each one. A nonlinear relationship is determined and modeled as an S-
shaped curve, according to qualitative data derived from the literature. It is represented as 
follows: 
Indicated Fraction (IF) = 
 
































PG(t) is the performance gap and the constant variable Normalized parameter (g) 
defines the slope of the S-shaped curved. PG(t)=0 is the inflection point where Indicated 
Fraction (IF) = 0.5, which shows that half of the investment is dedicated to the R&D 
activities and the other half  is spent on generating knowledge through external 
knowledge.  
However, a time delay exists from the moment of distinguishing the need for change to 
the time that the decision to change is actually applied. Thus, the allocation of funds is 
based on a perceived fraction, which is defined in our model by Actual Fraction (AF), 
where ATF (Adjustment Time for Fraction) in the model is the time it takes to react to the 
Indicated Fraction (IF). This delay and other similar delays are modeled here as an 
exponential smoothing. According to Sterman (2000), exponential smoothing means that 
the perceived value gradually adjusts to the actual value of the variable. The belief is 
constantly revised until the error is eliminated. This smoothing is necessary since the 
effect of changing a variable cannot be perceived instantly after measuring the actual 
value.  
 
4.2.4. Knowledge of the firm 
Each successful innovation project brings a value to the firm, either internally or 
externally. The amount of knowledge gained from each of these sources varies. As 
discussed earlier, R&D projects are inherently riskier than external projects, but have 
higher returns than external sources. The Acquired Knowledge of Internal Innovation 
(AKII) is the value of fraction of undertaken projects that are successful, and modeled 
here as follows: 
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= CRP * RSR * VRD (4-3) 
 
CRP (Completed R&D Projects) is the numbers of completed R&D projects in each 
quarter, RSR (R&D Success Rate) is the success rate of R&D projects and VRD (Value of 
R&D) is the average value of R&D projects. Since RSR and VRD are typically constant, 
the variability in the knowledge acquired through internal innovation is a function of 
CRP. 
Similarly, the knowledge obtained through external sources, Acquired Knowledge of 
External Innovation (AKEI) is the value of fraction of external projects that are 
successful, and modeled as follows: 
     
  
 = CEP*ESR*VEX (4-4) 
Where CEP (Completed External Projects) is the numbers of completed external 
projects in each quarter, ESR (External Success Rate) is the success rate of external 
projects and VEX (Value of External) is the average value of knowledge gained through 
external sources. Likewise, the ESR and VEX are constant and the variability in the 
knowledge acquired through external innovation is a function of CEP. It should be noted 
that VRD is greater than VEX but RSR is less than ESR because the R&D projects are 
much riskier than external projects. 
The knowledge level of the firm is defined here as a stock, Knowledge Value (KV), 
and illustrated in Figure 4.9. The changes in the Knowledge Value (KV) stock depend on 




Figure ‎4.9 The dynamic model of Knowledge Value 
The level of the firm‘s knowledge is also changing because of the knowledge loss. 
The outflow, Lost Knowledge, represents the fractional knowledge lost due to a variety of 
reasons, including not using the technology and saving it for the future, the departure of 
key employees, or even new technology replacing old technologies. The outflow is 
modeled as  
     
   
 , where KV (t) is the value of the firm‘s knowledge stock and TLK 
(Time to Lose Knowledge) is a constant representing the length of time in quarters in 
which knowledge is lost. The total knowledge stock value at time t is illustrated by the 
following equation:  
KV (t) = 
     
  
 





       
   
















4.2.5. External and Internal projects  
At each quarter, the firm undertakes External Projects (EP), and R&D Innovation 
Projects (RIP). RIP is a function of the funds available for research activities such that  
RIP =
   
   
 (4-6) 
Where ACR (Average cost of R&D) is a constant which equals the average cost of a 
R&D project, and IFA (Internal Fund Allocation) is the function of Fund For Research 
(FFR) and Actual Fraction (AF) that represents the available funds for conducting in-
house R&D activities.  
IFA = Fund for research (FFR)*(1- Actual Fraction (AF)) (4-7) 
The number of external projects (EP) are acquired by the firm is also dependent on 
the firm‘s absorptive capacity. Therefore, it is defined as follows: 
EP = 
   
   
                          (4-8) 
Where ACE (Average Cost of External) is a constant which equals the average cost 
of a project that is obtained from outside of the firm and EFA (External Fund Allocation) 
is the function of Fund For Research (FFR) and Actual Fraction (AF) that represents the 
available funds for obtaining external knowledge.  
EFA = Fund For Research (FFR)* Actual Fraction (AF) (4-9) 
Moreover, the average time required for completing or gaining R&D projects and 
external projects are different. Thus, they are modeled in the system as TR (Time to 
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complete a R&D project) and TE (Time to complete an external project) for internal 
projects and external projects, respectively.  
 
4.2.6. Financial resources 
As it can be seen in Figure 4.10, the second reinforcing loop is R2. This loop shows 
that as the firm generates more knowledge, the firm will have more access to venture 
capital either by licensing their patents or signalling venture capital investors where there 
is an avenue for further development in which they can invest (Niosi, 2000). By having 
access to a greater source of funds, the firm is able to spend more on research activities. 
Therefore, with some delay, the firm‘s effort leads to an increase in its knowledge stock. 
 
 
































Although the system based on the characteristics of the reinforcing loop, desires to 
keep investing on its own R&D, the financial resources are limited and the investment on 
R&D activities cannot last for the long term. As the firm invests more in R&D, it will 
have less money to introduce a new product into the market, which causes a decrease in 
available funds and subsequently impacts the amount of investment for future research 
(Khilji et al., 2006). These relationships are represented in Figure 4.11 by loop B2.  
 
Figure ‎4.11 The second balancing loop B2 
Therefore in the simulation model, the required funds for performing the discovery 
stage, (i.e. the early stage), Fund For Research (FFR), are modeled as a stock (see Figure 
4.12). These funds are used both for conducting in-house research and for knowledge 
acquisition from external resources. The inflow to this stock is called Investment For 

































    
  
                   (4-10) 
SI (t) = II*KSE (4-11) 
Where SI (Standard Investment), the funds that the firm can acquire in each quarter, 
is a function of the Initial Investment (II) and the Knowledge Stock Effect (KSE). II is a 
constant and is defined as the quarterly standard fund available for the discovery stage 
and KSE is a function of the knowledge value, KV (t). KSE represents that the firm in 
addition to gaining benefit from external sources of funds, such as the government and 
venture capital, can earn revenue from its stock of knowledge.  
The limitation of R&D activities in the simulation model is applied by the variable 
called Fractional Investment. However, since the effect of this reduction is not 
immediate, the actual FI is used in the model by considering exponential smoothing 
delay, where In. Adjustment Time (IAT) in the model is the time delay of realization of 
this decrease in the financial resources (see Figure 4.12). The Fractional Investment is 
formulated as follows. 
FI = MI + (1-MI) * 
1/ (1+EXP (Normalized parameter (g2)*(CCF - AF))) 
(4-12) 
Where Min Investment fraction (MI) is a constant that determines the minimum 
percentage of investment on the whole research process either internally, or otherwise 
externally if the firm focuses all its attention on the external resources. The constant 
variable Normalized parameter (g2) defines the slope of the S-shaped curve and Critical 
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Collaboration Fraction for reinvestment (CCF) is also a constant that represents the 
fraction of allocation in which the investment for research activities starts declining. 
The outflow of this stock models the allocation of available funds to internal and 
external projects: 
EFA = 




          
  
 (4-14) 
Where FFR (Fund For Research) is the total funds available for investing in both 
internal and external projects, AF (Actual Fraction) is a function of the performance gap 
as previously defined and Td (Time to Deplete) is the time delay in using the available 
fund. 
Thus, the Fund For Research (FFR) stock at time t is demonstrated by the 
following equation: 
FFR (t) = 
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Figure ‎4.12 The dynamic model of Fund for Research 
 
4.2.7. Absorptive capacity 
R&D activities, in addition to being a major source of knowledge, provide the firm 
with the ability of absorbing external sources of knowledge. This creates our third 
reinforcing loop, which is called R3 (see Figure 4.13), and demonstrates that more 
investment in internal R&D leads to an increase in absorptive capacity. Absorptive 
capacity is regarded as an important factor for absorbing external knowledge (Cohen and 



























ability of the firm to get involved in alliances and in collaboration activities that 
ultimately yield knowledge for the firm.  
 
 
Figure ‎4.13 The third reinforcing loop R3 
Absorptive capacity in this model is modeled as a function of Actual Fraction (AF) 
and has a value between 0 and 1. When the performance gap is zero, the AF is 0.5 and the 
Absorptive Capacity (AC) is 0.97. This high value for AC is set because the firm at the 
initial condition has no gap in the system, which means that the firm initially has enough 
absorptive capacity to identify, assimilate, and exploit knowledge outside of the firm. 
Focusing more on external resources and less on internal activities leads to a steady 
decline in the absorptive capacity. However, the slope and the amount of this decrease 
vary for each firm depending on the firm‘s skills and number of employees. Absorptive 


































Actual Absorptive Capacity (AAC) = 
 
                                  
 (4-16) 
Where   and Fac are constants that determine the slope and the shape of the AC 
versus AF. However, by increasing or decreasing the level of R&D activities, the 
absorptive capacity will not go up or down right away, respectively. In the real situation, 
there is a smoother response to the changes in R&D activities. By adding an exponential 
smoothing delay (perception delay), the absorptive capacity can be adjusted gradually 
over time (TAC in the model), which is showed in the model by Absorptive Capacity 






5. Discussion of the findings 
5.1. Base Model 
As it was mentioned by Sterman (2000), the process of model testing involves 
controlled experimentation. In this regard, models should be initialized in a balanced 
equilibrium. Equilibrium means that all stocks in the system are unchanging. For having 
an equilibrium for a stock, the net rate of change must be zero, it means that their inflows 
and outflows to be equal. In the present model, equilibrium of Knowledge Value (KV) 
stock requires the following: 
Knowledge level change = Lost knowledge (5-1) 
Hence, the initial value of the Knowledge Value (KV) is set as follows: 
Initial knowledge value (KV*) =TLK * 
(
                          
   
+ 
                                   
   
) 
(5-2) 
Where the description of the variables are as follows: 
Parameter Definition 
Normal Frac The initial allocation ratio  
II Initial investment  
VRD Value of R&D projects 
RSR R&D project success rate 
ACR Cost of R&D projects 
VEX Value of external projects 
ESR External project success rate 
Initial AC Initial value of absorptive capacity  
ACE Cost of external projects 
TLK Time for knowledge to become lost 
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From the equilibrium function, it can be concluded that the equilibrium knowledge 
value is high if the values and success rates of external and internal projects are high. The 
initial absorptive capacity of the firm, as well as the funds allocated for the discovery 
stage, also have a direct impact on the equilibrium knowledge value. However, the high 
R&D expenditure and the high cost of external projects leads to the low knowledge value 
in equilibrium.  
In order to capture the dynamics of the model, after setting the equilibrium values, 
we first need to initiate the model without any exogenous influences. The base case 
model, which is illustrated in Figure 5.1 and Figure 5.2, represents the behaviour of the 
model in this situation for the Performance Gap and Actual Fraction variables. The base 
case is tested assuming that the Target knowledge value is the same as Initial knowledge 
value, where ultimately the Performance Gap is zero. This means that the fraction of 
funds allocated to either R&D activities or external knowledge is the same and is equal to 
0.5 for each. It is also hypothesized that there is enough absorptive capacity to acquire 




Figure ‎5.1 Base case: Performance Gap of the base case model 
 
Figure ‎5.2 Base case: Actual Fraction of the base case model 
 
For testing different scenarios in the model, a two years equilibrium period (eight 
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knowledge through in house activities and acquiring knowledge from external resources. 
After this point in unit time, the firm decides which sources of knowledge to focus on 
based on the value of the performance gap variable. As it was stated previously, in the 
case of positive the performance gap, the greater attention is paid on acquiring knowledge 
from external sources. In this model we investigate through simulation runs the effect of 
using external knowledge and establishing the strategic alliances on the knowledge 
performance gap. In the following parts the effect of size of the gap, R&D expenditures 
and the firm‘s initial orientation towards using external resources of knowledge on the 





5.2. Increase in target by 10%, 30% and 50% 
To see how the model reacts to different amounts of increase in the performance 
target, the target is increased by 10%, 30% and 50% in the time 8 (quarters) in three sets 
of runs. The proportional results of these runs for Performance Gap variable are shown in 
Figure 5.3.  
 
Figure ‎5.3 Performance Gap for 10%,30% & 50% increase in target 
The model is simulated over a time period of 100-quarters, where the target 
knowledge value is increased by 10%, 30% and 50% and they can be distinguished by 
green, red and blue lines, respectively. It can be seen that the firm is able to gradually 
reduce the generated gap because of the increase in the target by acquiring its required 
knowledge through utilizing external acquisition and partnership with other firms and 
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By increasing the target (i.e. 10% to 50%), the Performance Gap becomes positive 
(i.e. 0.08 to 0.35). In order to bridge the gap as soon as possible the firm will focus more 
on the fast and certain strategy of exploiting knowledge from external resources. In this 
situation, the system instantly responds to this increase in target by allocating more 
financial resources to acquire external knowledge rather than conducting in house R&D 
activities. However, it takes time to make some collaboration contracts or acquire 
relevant knowledge, which is why the gap is steady until the time of 15 quarters. After 
this point in unit time, the required knowledge will come into the firm and feed into the 
Knowledge Value (KV) stock and this leads to shrinking the observed gap between the 
actual knowledge and the target knowledge. 
 In Figure 5.3, a very smooth oscillation is noticed in the trend of changes for the 
Performance Gap, which can be justified by the relation of Performance Gap and Actual 
Fraction (AF). Once the firm observes that the gap is lessened, it will allocate little more 
funds to the internal activities and since they pay off late, the gap slightly increases. 
However, this increase is not significant and does not affect the decision of allocating 
more on acquiring external knowledge, and ultimately the gap starts declining.  
To conclude this experiment, the firm which is in need of the gain of additional 
knowledge, it can gain the required knowledge through focusing on the fast and less 
risky strategy of the knowledge acquisition from external sources. i.e. it will search 




5.3. Increase in target by 100% 
The model is also tested when the target is doubled compared to the base case. The 
result is shown in Figure 5.4 in comparison to 50% increase in the target.  
 
Figure ‎5.4 Performance Gap for 50% & 100% increase in target 
Once the target is doubled, it was expected that the system will put in more effort 
into acquiring knowledge through external resources to fulfill its immediate need of new 
information and knowledge. Figure 5.4 represents this situation. Initially, the gap starts 
closing until the time of 26 quarters, but then the performance gap grows. By doubling 
the target, the firm needs more knowledge from external resources, and then it will 
allocate more money to acquire this knowledge. The increase in the allocation to external 
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Figure ‎5.5 Actual Fraction for 50% & 100% increase in target 
Therefore, the firm will have less money to invest in R&D activities and this leads to 
a gradual decrease in the absorptive capacity, as demonstrated in Figure 5.6. The results 
is also consistent with the study conducted by Deeds and Hill (1996), in which 
structuring strategic alliances initially benefits the firm by providing it with a quick set of 
complementary assets, but as a result of focusing more on this strategy, there is some 
diminishing and negative returns at some points. This model shows (see Figure 5.4) that 
for the short term, using external knowledge and partnership can reduce the gap (around 
25 quarters), but putting more emphasis on this strategy leads to a considerable distance 
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Figure ‎5.6 Absorptive Capacity for 50% & 100%increase in target 
The observed decrease in Absorptive Capacity (see Figure 5.6) means that the firm 
cannot use the external knowledge efficiently, so the number of projects will decrease as 
demonstrated in Figure 5.7. It can be inferred that since the gap is too large, a great 
Knowledge Value is required to reduce the Performance Gap. Although acquiring 
external knowledge is less risky and has quicker return, it has lower value and cannot 
resolve this difference. On the other hand, not paying enough attention to the internal 
R&D activities leads to decrease in Absorptive Capacity level, which is very important 
for obtaining external knowledge. Hence, the combination of these two situations results 
in a wider gap.  Therefore, the decrease in the knowledge level will be misunderstood by 
focusing more on the external knowledge, which ultimately leads to the dramatic increase 
in the size of the gap and the gap will not be closed in the long term (see blue line in 
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The main conclusion stemming from this exercise is that the external knowledge 
strategy is effective for a small amount of increase in the innovation target, but it is 
not a suitable strategy when the firm needs to gain a substantial amount of 
knowledge for large scale innovative plans.  
 
Figure ‎5.7 Quarterly Complete External Projects (CEP) 
5.4. The response of the gap to the R&D cost changes 
The effectiveness of the external knowledge acquisition strategy cannot only be 
judged by the amount of increase in the performance target. As Figure 5.8 demonstrates, 
the same increase of 60% in the target was tested for both the initial condition (condition 
of the base case model) and when the R&D activities cost less for a firm. This is usually 
the case of large firms, where they have a lower R&D expenditure due to the economies 
of scale, which results in a higher return for the firm (Van Moorsel et al., 2007).  As can 
be seen in Figure 5.8, adopting external policy is not effective for long term when the 
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R&D expenditure decreases. It can be observed from the simulation results that when the 
ratio of the cost of R&D (ACR)  to the value of R&D (VRD) projects is approximately 
close to the ratio of the cost of external (ACE) to the value of external (VEX), focusing on 
external resources is not beneficial.  
The growing gap can be justified through the equilibrium equation of Knowledge 
Value (KV) stock (equation 5-2). Considering the cost of R&D (ACR), which is given in 
the denominator of the fraction, the KV* goes up by decreasing this cost, bearing in mind 
that we did not change the knowledge acquired by external innovation. Thus, by 
increasing the target even more, the firm should put more effort into its external sources 
to compensate the gap. By focusing more on knowledge acquisition and partnership, the 
firm will lose its Absorptive Capacity (AC) and turns into a negative feedback loop, 
where focusing on knowledge acquisition from outside of the firm results in a larger gap. 
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Figure 5.9 illustrates that even when the increase in target is low (20%) and the R&D 
expenditures are low (around half compared to the base case model), concentrating on 
strategic research alliances and outside knowledge in the long term leads to an increase in 
the generated gap of actual knowledge and performance gap (green line). This led to the 
conclusion that the cost of the R&D projects (ACR) also can affect the decision making in 
terms of the preference for the external resources when the firm falls behind its 
knowledge target. Therefore, when the cost of R&D projects is low and their return is 
high, the acquisition and partnership is not an effective policy and for adopting this 
policy other parameters should be taken into account.  
 
Figure ‎5.9 The effect of lower cost of R&D on the Performance Gap 
5.5. Resource allocation between external & internal  
To see the effect of the firm‘s initial policy towards allocation of funds for R&D 
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(1) a firm with high R&D intensity (75% of its available funds are allocated to in-house 
research activities); (2) a firm with low R&D intensity (30% of its available funds are 
allocated to in-house research activities).  
 
5.5.1. Scenario (1) 
Figure 5.10 displays the Performance Gap for the 20% and 60% increase in the 
performance target for both base cases: when the initial fraction of R&D activities is 0.5 
and for scenario (1): where the initial fraction of R&D is 0.75. The Absorptive Capacities 
(AC) of these runs are also shown in Figure 5.11. 
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Figure ‎5.11 Absorptive Capacity for scenario (1) and the base case 
As seen in Figure 5.11 (green and gray lines), the firm which has already invested 
most of its funds in R&D activities, has accumulated a vast pool of knowledge and hence 
a high Absorptive Capacity (AC). This accumulated knowledge and absorptive capacity 
provide the firm with the capability to exploit the outside knowledge effectively. 
Therefore, the higher range of external knowledge can be exploited to close the gaps, 
which ultimately results in a faster response. Therefore, it can be concluded that when 
there is an increase in target, investing more in the external sources of knowledge 
for firms with a high R&D intensity brings fast results, even for a larger 
performance gap. The steeper slopes of the green and gray line in Figure 5.10 shows 
this quick decline is the Performance Gap. Since these firms already sustain their place in 
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external knowledge or structure collaboration partnerships, they can compensate a sudden 
increase in target by relying more on external knowledge. 
 
5.5.2. Scenario (2) 
Figure 5.12 illustrates the Performance Gap for the 20% and 60% increase in the 
performance target for both base cases: when the initial fraction of R&D activities is 0.5, 
and for scenario (2): where the initial fraction of R&D is 0.3. The Absorptive Capacity 
(AC) of scenario (2) is set the same as the base case and they both start from one point, 
which is 0.97. The Absorptive Capacity graphs are also shown in Figure 5.13. 
The graphs show that there is not a significant difference between the initial 
condition (50% allocation of fund to R&D activities) and this scenario. From these 
results, we can infer that when the firm has already spent more than 50% of its funds 
on establishing collaborative agreements and acquiring external knowledge, it can 
close small gaps in its knowledge performance by pursuing this strategy. However, 
as previously explained, this strategy is only efficient for small gaps, while for larger 




Figure ‎5.12 Performance Gap trend for scenario (2) and the base case 
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5.6. Combination of initial resource allocation and R&D expenditure 
To improve our understanding of the system‘s responses to the firm‘s initial policy 
towards allocating funds for internal R&D and external sources of knowledge, the 
simulation model was tested for the following scenarios: 
 Scenario (3): high R&D intensity and low cost of R&D 
 Scenario (4): high R&D intensity and high cost of R&D 
 Scenario (5): low R&D intensity and low cost of R&D 
 Scenario (6): low R&D intensity and high cost of R&D 
 
5.6.1. Scenario (3): The combination of high R&D intensity and low cost 
The 20% and 60% increase in target was examined for the condition in which the 
initial fraction of R&D is 0.75, which means that the firm has a high R&D intensity and 
the R&D expenditure is lower compared to scenario (1). Figure 5.14 illustrates the 
Performance Gap of the 20% and 60% increase in target for this initial condition and 
previously explained scenario (1). Blue and red lines represent the trend of Performance 




Figure ‎5.14 Performance Gap for scenario (3) and scenario (1) 
As seen in Figure 5.14, the firm can compensate the generated gap by focusing more 
on the external source of knowledge, even in a situation with a lower cost of R&D. 
However, the level of changes is shifted higher compared to scenario (1) (grey and green 
lines). Generally, for a high R&D intensive firm, the firm can gradually close the gap by 
allocating more money to external sources.  
In fact, the firm already has an appropriate stock of internal knowledge (See Figure 
5.15) the value which is greater than the stock of external knowledge (See Figure 5.16). 
Thus, the firm is able to satisfy its need for extra knowledge by allocating little more 
funds to external activities. Furthermore, while the performance gap starts closing, the 
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This synthesis results in an effective combination of R&D activities and 
collaborative efforts, which leads to a faster response to the gap even if the lower R&D 
cost slightly shifts this behaviour. It should be noted that if the cost is very low, the gap 
will start growing. However, this case does not usually happen since the R&D 
expenditure in biotechnology is inherently high.  
 
 
Figure ‎5.15 Knowledge acquired by internal R&D for scenario (3) and scenario (1) 
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Figure ‎5.16 Knowledge acquired by external resources for scenario (3) and scenario (1) 
This leads to the conclusion that when there is an increase in target, even with a 
low R&D cost, investing more in external sources of knowledge for firms with a high 
R&D intensity brings faster results, even for a larger performance gap. 
 
5.6.2. Scenario (4): The combination of high R&D intensity and high cost 
Figure 5.17 demonstrates the Performance Gap for a 20% and 60% increase in target 
for the condition in which the initial fraction of R&D is 0.75, which means that the firm 
has a high R&D intensity, and the R&D expenditure is higher in comparison to scenario 
(1). 
















"Acquired knowledge of external innovation (AKEI)" : 20% - High R&D intensity and low cost
"Acquired knowledge of external innovation (AKEI)" : 60% - High R&D intensity and low cost
"Acquired knowledge of external innovation (AKEI)" : 20% - High R&D intensity




Figure ‎5.17 Performance Gap for scenario (4) and scenario (1) 
As shown by the red line and blue line in Figure 5.17, there is a steeper drop in the 
gap compared to scenario (1), when there were no changes to the R&D cost. It can be 
concluded that when the cost of R&D is high and the firm is highly R&D intensive, 
there are more benefits to acquiring knowledge from outside of the firm, even for 
the larger gap. However, we can see a rather soft oscillation behaviour in the 
Performance Gap trend, which is the result of shifting focus from R&D to external and 
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5.6.3. Scenario (5): The combination of low R&D intensity and low cost 
Figure 5.18 shows the Performance Gap for a 20% and 60% increase in target for 
the condition in which the initial fraction of R&D is 0.3, which represents a firm with low 
R&D intensity, and the R&D expenditure is lower in comparison to scenario (2).  
 
. Figure ‎5.18 Performance Gap for scenario (5) and scenario (2) 
As observed from the simulation results in Figure 5.18, when the firm initially 
allocates smaller amounts of funds to the R&D activities while the R&D cost is low, it 
cannot reduce the generated gap by focusing more on its former policy, which was 
acquiring knowledge externally. Even for a slight increase in target (20%), the firm is not 
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5.6.4. Scenario (6): The combination of low R&D intensity and high cost 
Figure 5.19 shows Performance Gap in two sets of tests for a 20% and 60% increase 
in target for low R&D intensity firms that have a low R&D cost (scenario 5) and a high 
R&D cost (scenario 6). 
 
Figure ‎5.19 Performance Gap for scenario (5) and scenario (6) 
 
As shown in Figure 5.19, there is only a slight difference between the low R&D cost 
and high R&D cost in the test runs and the gap ultimately grows for both of them.  
It must be taken into consideration that in a low R&D intensity environment, the firm 
has a lower stock of R&D knowledge. Therefore, no matter whether the cost of R&D is 
low or high, the firm is not able to manage the generated gap by directing more efforts 
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On the one hand, the knowledge value brought by external acquisition is not high 
enough to close this gap, and on the other, the firm is unable to make these collaborations 
due to its low level of internal knowledge and Absorptive Capacity (AC). In the other 
words, the firm does not have a strong research and product development platform to 
attract other companies and institutes to make collaborative agreements. This is also 
consistent with several studies that have shown that there is a positive correlation 
between higher levels of R&D spending and a higher level of collaboration (Hall and 
Baghchi-Sen, 2007; Bagchi-Sen, 2004; Deeds and Hill, 1996; Freeman, 1991). 
Companies with strong research and developmental capabilities have a greater potential 
to become partners and collaborate more effectively (Arora and Gambardella, 1994; 
Nambisan, 2002). Conversely, it can be argued that in firms with little in house research 
knowledge, the opportunity to develop collaborations and absorbing external knowledge 
is not easily available. 
This in-depth analysis for the different scenarios of the simulation model reveals that 
the acquisition of knowledge is not an efficient strategy for firms with a low R&D 
intensity, i.e. when the firm spends less than 50% of its fund on R&D activities, no 
matter whether the cost of R&D is high or low for the firm and for adopting this 




5.7. Validation methods in system dynamics  
Barlas and Kanar (2000) argued that the validation of the system dynamics model 
involves two components: structure validation and behaviour validation.  Structure 
validation evaluates whether the relationships developed in the model adequately 
demonstrate the real relationships. Behaviour validation means that we want to make the 
behaviour of the model as close as possible to the anticipated behaviour of the real 
system.  
The structure validation can be applied by two ways; (a) direct structure testing (b) 
indirect structure (or structure-oriented behaviour). In direct structure validity tests, the 
model is compared to the real system structure.  In this test, the mathematical equations 
or other forms of the relationship are evaluated against the real system. Since these tests 
are qualitative, simulation is not involved. On the other hand, Structure-oriented 
behaviour tests indirectly evaluate the validity of a model through applying certain 
behaviour test on a model that involves simulation. For example, one of the methods is 
extreme condition testing, in which the extreme values are assigned to the selected 
parameters. Then, the generated behaviour of model will be compared to the expected 
behaviour of the real system under the same extreme conditions.  
 
5.7.1. Validation of the current model  
As mentioned above, validation can be performed from two different perspectives: 
validation of the structure of the model or validation of the behaviour of the model. 
Regarding the structural validation of the model in this study, all of the elements of the 
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model are retrieved from the available literature. Thus, the model equations and their 
relationships are developed based on the existent literature.  
Considering the behavioural validation, three sets of condition have been tested in 
the model: (a) the condition in which the firm is ahead of its target, (b) the condition in 
which the firm is ahead of its target and there are unlimited financial resources due to 
more focus on R&D and (extreme condition method) (c) the condition in which the firm 
has more access to financial resources. 
To test condition (a), a negative gap, which means that the firm performs well and is 
ahead of the target was imposed on the system to check the model-generated behaviour. 
It was expected that the firm initially focuses more on internal activities since it is ahead 
of its schedule and can invest in a new product to create and sustain the competitive 
advantage. However, after a while its financial resources become limiting because of the 
long-run return of R&D activities and the lack of commercial products during this time. 
Therefore, both internal and external projects decline due to the lack of available fund 
and as a result the firm‘s performance is affected and leads to a fall in its knowledge 
stock.  
The model‘s results satisfied our expectations. The results of the model are shown in 
comparison with the positive gap. As it shown in Figure 5.20 (blue line) , the 
Performance Gap was negative at first but as the time passes, the number of ongoing 
projects decreases due to the reduction in the financial resources. The knowledge they 
bring to the firm gradually diminishes (see Figure 5.21 and 5.22) and this leads to an 




Figure ‎5.20 Performance Gap of condition (a) 
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Figure ‎5.22 Knowledge gained by external innovation for condition (a) 
Condition (a) and condition (b) only differ in terms of the limitations of financial 
resources. Condition (b) tests the situation in which there is no shortage of the financial 
resources created as a result of spending most of the available funds on R&D activities. 
The anticipated behaviour is that the firm would mainly maintain this strategy since it 
results in a higher return without making any constraints for the firm. As demonstrated in 
Figure 5.23, when the firm performance is negative, the firm will invest more in internal 
innovation and since there are no limitations in the funding resources, the firm intends to 
focus more on the R&D. As shown in Figure 5.23, it can keep this difference for a long 
term. However, this decrease in the knowledge level is due to the long term return of 
R&D projects.  
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Figure ‎5.23 Performance Gap of condition (a) 
In condition (c), it was expected that when the firm has more access to the financial 
resources, it can perform more projects and can exceed its target to make the gap 
negative. Figure 5.24 demonstrates that by increasing the standard investment (SI) by 
20%, the number of projects, either internal or external, will also go up. The knowledge 
level of the firm also increases and the firm performance is improved. The increases in 
the knowledge gained internally and externally are shown in Figure 5.25 and 5.26, 
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Figure ‎5.24 Performance Gap of condition (c) 
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In this research, system dynamics methodology is employed to describe and 
formalize the relationships between critical factors in the early stage of the innovation 
process in biotechnology. In order to accomplish this objective, relevant literature was 
reviewed first. This helped us find the most influential factors that shape the early stage 
of the innovation process in biotechnology. Afterwards using the system dynamics 
approach, the relationships and interactions among these factors were examined and a 
series of causal loop diagrams illustrating their dynamics and the feedback mechanisms 
were developed. These causal models were then transformed to a computer simulation 
model, which enabled us to observe the behaviour of the whole system. The developed 
model presents an exploratory and rather detailed view of the factors influencing 
decisions made by a biotechnology corporation in the early stage of the innovation 
process.  This research contributes to the advancement of knowledge by providing a 
better understanding of (a) the structure of the system, including elements and their 
relationships, and (b) the behaviour of the system in the early stage of innovation.  
In this regard, this thesis introduces five causal loops as the main pillars of the 
interactions among these components: knowledge creation, knowledge accusation, capital 
raising, venture capital investment, and R&D lock-in. Internal R&D activities and 
external sources of knowledge (such as knowledge acquisition and partnership) provide 
knowledge for innovation in the biotechnology firms. It is widely recognized that 
scientific and research capabilities have a significant impact on the biotechnology 
innovative performance.  
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R&D activities play an important role in the creation and enhancement of 
biotechnology professional competences by providing firms with both the essential 
source of innovation and the firm‘s ability to learn. On the other hand, the presence of 
external networks, the existence of markets for certain technologies, growth barriers and 
the absorptive capacity all have an important impact on the process‘ effectiveness. This 
emphasizes the significant role which external sources of knowledge play in competitive 
conditions. In addition to considering both the external and internal sources, it is also 
important to take into account the balance between these sources. In this regard, the main 
objectives of the research pertain to how the biotechnology firm can maintain the right 
balance between adopting in house activities vs. structuring external collaboration and 
how it can execute its innovation plans while using the appropriate combination of these 
different sources of knowledge.  
To achieve these objectives, the initial status of the computer simulation model is set 
in order to observe the system‘s behaviour under various settings of the model‘s factors. 
This thesis investigates the critical factors influencing the firm‘s decisions and polices 
regarding the employment of the most suitable combination of the internal and external 
sources of knowledge in order to increase the firm‘s innovative productivity. Our 
findings are summarized below:  
 To maintain performance expectations, a firm should utilize distinct strategies for 
acquiring knowledge, depending on the firm‘s innovative goals and other internal 
factors. 
 For a firm that initially allocates the available funds for research equally between 
internal and external sources of knowledge, an increase in its innovative target 
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should lead to an increased focus on the exploitation of external sources of 
knowledge. This means that the firm should commit the available funds to the 
establishment of collaborative agreements. However, if the firm‘s innovative 
goals are too ambitious and hence its knowledge target is too high, exploiting 
external sources of knowledge appears to be a suitable short-term strategy but 
may not be effective in the long run. Another factor influencing the fund 
allocation decision is the cost of R&D projects for a firm. For a firm with a 
relatively low cost of R&D, external sources may not be effective anymore, since 
R&D projects are cheaper and thus create higher returns for a firm than the 
external sources of knowledge can generate. 
 In a highly competitive environment in which introducing a new product is 
required, focusing on the external knowledge acquisition is a highly efficient 
strategy for high R&D intensity firms. Since these firms initially spend the 
majority of their available funds on internal R&D activities, they manage to build 
a high level of absorptive capacity. As a consequence, they are able to quickly 
and easily absorb external knowledge, to integrate it with their prior knowledge 
efficiently and to generate a great innovative potential needed for the new 
product development. 
 For low R&D intensity firms who spend less than 50% of their available funds 
on in house R&D activities, the strategy of focusing primarily on external 
knowledge sources and seeking numerous collaborative agreements requires a 
very careful assessment. A short-sighted policy of exploiting mostly external 
knowledge, without taking into account the firm‘s absorptive capacity level, may 
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prevent a firm from ever reaching its expected innovative goals, even if there are 
some temporary improvements in the beginning.  
 
The findings of this research have could also be used as normative suggestions for 
decision makers in the companies. Although this research provides the general insights 
for policy makers, there is still a need for a customized model that is based on the specific 
characteristics of a biotechnology firm in order to develop effective policies. Therefore, 
one future research direction can involve an empirical study for a specific biotechnology 
firm.  
Several other future research directions are recommended based on the results of this 
study. First, the allocation process is based only on funding resources, neglecting other 
resources such as human resources. Therefore, future research can be focused on other 
aspects of the resources, such as scientists, since their importance is extremely 
emphasized by existent literature in the success of biotechnology firms. Second, the 
effectiveness of involvement in the external scientific community is only investigated 
through the value of the knowledge they bring to the firm, but there may be other reasons 
why external sources are valuable that our model did not demonstrate. Thus, a future 
study can focus on other reasons such as empowering the external communication 
channels or seeking new paradigms of technology. Third, the only independent variable 
evaluated in our model was the increase in the innovation goal. The rate of change in the 
market place and the change in the required type of innovation are other factors that may 
greatly influence the R&D versus external sources focus. These factors can be considered 
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Appendix A- Lists of Vensim model equations 
-------------------------------------------------------------------------------------------------------------------------------- 
(01)      "Absorptive Capacity (AC)"= INTEG (Change in AC level, 
 "actual AC value (AAC)") 
 Units: AC [0,1,0.01] 
 The ability of firm in recognizing the value of external knowledge and apply it to 
commercial end 
 
(02) ACE= 250000 
 Units: $ 
 Average fund required for conducting each collaborative project 
 
(03) "Acquired knowledge of internal effort (AKII)"= "succeeded R&D projects 
(SIP)"*"Value of R&D projects (VRD)" 
 Units: Knw/Quarter 
 Amount of knowledge gained each quarter by R&D projects 
 
(04) ACR=1.2e+006 
 Units: $/project 
 Average fund required for conducting each R&D project 
 
(05) "actual AC value (AAC)"=1/(1+EXP(Beta*(F ac-"Actual Fraction (AF)"))) 
   
(06) Actual FI= INTEG (change in AFI, "fractional investment (FI)") 
   
(07) "Actual Fraction (AF)"= INTEG (change in F, "Indicated fraction (IF)") 
   
(08) "Acquired knowledge of external innovation (AKEI)"="succeeded external projects 
(SEP)"*"Value of collaboration projects (VEX)" 
 Units: Knw/Quarter 
 Amount of knowledge gained each quarter by partnership projects 
 
(09) "adjustment time (ATF)"=3 
 Units: Quarter 
  
(10) Beta=-8 
   
(11) Change in AC level=("actual AC value (AAC)"-"Absorptive Capacity (AC)")/"Time to 
adjust AC (TAC)" 
 Units: AC/Quarter 
 Change in Ac level 
 




(13) change in company performance=("Indicated knowledge stock effect (IKSE)"-
"Knowledge stock effect (KSE)")/"Time to adjust company performance (TACP)" 
   
(14) change in F=("Indicated fraction (IF)"-"Actual Fraction (AF)")/"adjustment time (ATF)" 
   
(15) "Complete external projects (CEP)"= DELAY3("External Projects (EP)", "T External 
(TE)") 
 Units: project/Quarter 
 Number of complete and successful R&D projects 
 
(16) "Complete R&D projects (CRP)"= DELAY3("R&D innovation Projects(RIP)", T R) 
 Units: project/Quarter 
 Complete successful R&D projects 
 
(17) "critical collaboration fraction for reinv (CCF)"= 0.35 
   
(18) Desired number of external projects="External source fund allocation (EFA)"/ACE 
   
(19) "External Projects (EP)"=Desired number of external projects*"Absorptive Capacity 
(AC)" 
 Units: project/Quarter 
 Number of partnership projects undertake in each quarter 
 
(20) "External source fund allocation (EFA)"=("Fund For Research (FFR)"*"Actual Fraction 
(AF)")/Td 
 Units: $/Quarter 
  
(21) "External success rate (ESR)"=0.85 
 Units: Dmnl [0,1] 
 Fractional rate of success for collaborative projects 
(22) F ac=0.9 
   
(23) FINAL TIME  = 100 
 Units: Quarter 
 The final time for the simulation. 
 
(24) "fractional investment (FI)"="min investmentfraction (MI)"+(1-"min investmentfraction 
(MI)")*1/(1+EXP("Normalized parameter (g2)"*("critical collaboration fraction for reinv 
(CCF)" -"Actual Fraction (AF)") )) 
 Units: Dmnl 
  
(25) "Fund For Research (FFR)"= INTEG ("Investment for research (IFR)"-("External source 
fund allocation (EFA)"+ 
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 "In house R&D fund allocation (IFA)"), Td*"Initial Investment (II)") 
 Units: $ 
  
(26) "In house R&D fund allocation (IFA)"= ("Fund For Research (FFR)"*(1-"Actual 
Fraction (AF)"))/Td 
 Units: $/Quarter 
  
(27) "In-house Projects (IP)"= INTEG ("R&D innovation Projects(RIP)"-"Complete R&D 
projects (CRP)", "R&D innovation Projects(RIP)"*T R) 
 Units: projects 
 Number of in house R&D projects 
 
(28) "In. adjustment time (IAT)"= 4 
   
(29) "Indicated fraction (IF)"=1/(1+EXP("Normalized parameter (g)"*"Performance Gap 
(PG)")) 
   
(30) "Indicated knowledge stock effect (IKSE)"="Knowledge Value (KV)"/Initial knowledge 
value 
   
(31) initial AC=1/(1+EXP(Beta*(F ac-Normal Frac))) 
   
(32) "Initial Investment (II)"=500000 
   
(33) Initial knowledge value="Time to lose knowledge (TLK)"*((1-Normal Frac)*"Initial 
Investment (II)"/ACR)*("Value of R&D projects (VRD)"*"R success rate (RSR)")+ 
("Time to lose knowledge (TLK)"*(Normal Frac*"Initial Investment (II)"/ACE)*initial 
AC*"Value of collaboration projects (VEX)"*"External success rate (ESR)") 
  
(34) INITIAL TIME  = 0 
 Units: Quarter 
 The initial time for the simulation. 
 
(35) Input=1+STEP(Step Height, Step Time ) 
   
(36) "Investment for research (IFR)"="Standard investment (SI)"*Actual FI 
 Units: $/Quarter 
  
(37) Knowledge level changes="Acquired knowledge of external innovation 
(AKEI)"+"Acquired knowledge of internal effort (AKII)" 
 Units: Knw/Quarter 
 Knowledge gained by firm either by R&D or Collaboration in each quarter 
 
(38) "Knowledge stock effect (KSE)"= INTEG (change in company performance,1) 
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(39) "Knowledge Value (KV)"= INTEG (Knowledge level changes-Lost Knowledge, Initial 
knowledge value) 
 Units: Knw 
 Amount of knowledge gained by firm 
 
(40) Lost Knowledge="Knowledge Value (KV)"/"Time to lose knowledge (TLK)" 
 Units: Knw/Quarter 
 Knowledge lost 
 
(41) "min investmentfraction (MI)"= 0.5 
   
(42) Normal Frac=0.5 
   
(43) "normal performance target K (NPT)"= Initial knowledge value 
   
(44) "Normalized parameter (g)"=-3 
 Units: Dmnl 
 Normalized parameter to adjust R&D and collaboration ratio 
 
(45) "Normalized parameter (g2)"=200 
   
(46) "Number of projects through external (EP)"= INTEG ("External Projects (EP)"-
"Complete external projects (CEP)","External Projects (EP)"*"T External (TE)") 
 Units: projects 
 Number of firm's projects that are co-authored with other firms and research institutes 
 
(47) "Performance Gap (PG)"=("Performance Target knowledge (PT)"-"Knowledge Value 
(KV)")/"Performance Target knowledge (PT)" 
 Units: Knw 
 THe gap which exists between the actual performance and target  performance 
 
(48) "Performance Target knowledge (PT)"= "normal performance target K (NPT)"*Input 
 Units: Knw 
 an initial value of firm's target in the early stage 
 
(49) "R success rate (RSR)"=0.5 
 Units: Dmnl [0,1] 
 Fractional success rate of R&D projects 
 
(50) "R&D innovation Projects(RIP)"="In house R&D fund allocation (IFA)"/ACR 
 Units: project/Quarter 




(51) SAVEPER  =  TIME STEP 
 Units: Quarter [0,?] 
 The frequency with which output is stored. 
 
(52) "Standard investment (SI)"="Initial Investment (II)"*"Knowledge stock effect (KSE)" 
   
(53) Step Height=0 
 Units: Dmnl 
 Height of step input for performance gap 
 
(54) Step Time=8 
 Units: Quarter 
 Time for change 
(55) "succeeded external projects (SEP)"="Complete external projects (CEP)"*"External 
success rate (ESR)" 
  
  
(56) "succeeded R&D projects (SIP)"="Complete R&D projects (CRP)"*"R success rate 
(RSR)" 
(57) "T External (TE)"=8 
 Units: Quarter 
 Average time for completing collaborative projects 
 
(58) T R=16 
 Units: Quarter 
 Average time required to complete R&D projects 
 
(59) Td=12 
 Units: Quarter 
 
(60) TIME STEP  = 1 
 Units: Quarter [0,?] 
 The time step for the simulation. 
 
(61) "Time to adjust AC (TAC)"=8 
  
(62) "Time to adjust company performance (TACP)"=5 
 Units: Quarter 
  
(63) "Time to lose knowledge (TLK)"=8 
 Units: 1/Quarter 
 Amount of knowledge which is lost in each quarter 
 
(64) "Value of collaboration projects (VEX)"=500 
140 
 
 Units: Knw/project 
 Value of knowledge acquired by undertaking joint project with other firms and 
universities and research institutes 
 
(65) "Value of R&D projects (VRD)"=1500 
 Units: Knw/project 
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